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A recently revived experimental screening procedure 
can detect some birth defects at least six weeks earlier 
than amniocentesis, allowing problems to be diagnosed 
in the first, rather than second, trimester of pregnancy. 
Laboratory Medieine 
Physicians often find it cheaper to perform lab tests in 
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several laboratory medicine specialists comment on 
these dilemmas, address the high cost and short-life of 
high technology, and describe their research. 
Uhiquitin 
A protein found in most organisms - from bacteria to 
humans - turns out to be a member of a family known 
as the heat shock proteins. Having sequenced its gene­
and found some unusual features - scientists would like 
to know how the protein, ubiquitin, protects cells against 
stress. 
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At Washington University School of Medicine, the pro­
tein interferon is helping some patients with kidney 
cancer and wart-like growths on the larynx. It may also 
be useful in the fight against childhood leukemia. 
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Diabetics - even those who appear to keep their blood sugar level s 
well-controlled - can be 
plagued by side effects of their 
disease. Damage to peripheral 
nerves and organs such as the 
kidney, together with growth of 
new blood vessels in the eye, 
are among the leading causes 
of diabetes-induced disability. 
But a group of new drugs, cur­
rently in clinical trials, may 
prevent potentially lethal 
developments. 
Glucose can be metabolized 
in several ways, leading to the 
formation of various end prod­
ucts including the sugar called 
sorbitol. Although all persons 
possess the enzyme capable of 
changing gJucose into sorbitol, 
non-diabetics have low levels 
of sorbitol because the ir glu­
cose level s are low. However, 
diabetics with high blood glu­
cose levels may convert up to 
30 percent of the glucose to 
sorbitol. 
Unfortunately, sorbitol isn't 
easily excreted by cells, and 
scientists think that it - or 
metabolic imbalances asso­
ciated with it - causes the 
Ii tany of ilis that can plague 
even the well-controlled diabe­
tic. So reducing or preventing 
the activity of the enzyme 
catalyzing the glucose-to­
sorbitol reaction may reduce 
the inc idence of ti ssue damage. 
Several drug companies are 
preparing to conduct human 
tests of drugs called aldose 
reductase inhibitors (ARls). 
These drugs (Sorbinil and Tol­
restat are the most-studied) 
prevent formation of sorbitol. 
But there hasn't been an animal 
model in which diabetes­
caused blood vessel changes, 
equivalent to those in human 
diabetics, can be induced read­
ily to permit documentation of 
ARls' specific effects. Such a 
model has been developed by 
Joseph R. Williamson, M.D. 
, 58, professor of pathology at 
Washington University. New 
blood vessels formed in the 
skin of diabetic laboratory ani­
mals show the same marked 
increase in permeability as ves­
sels in human diabetics. 
Williamson says that hi s ani­
mal model enables specific 
changes induced by the dia­
betic milieu to be documented 
and studied: "The most charac­
teristic functional abnormality 
in human diabetic vascular di s­
ease," says Williamson, "is 
that the blood vessels become 
leaky, so that the serum pro­
teins leak out of the vessels and 
into the tissue. You see this 
most dramatically in the eyes 
of poorly controlled diabetics. 
They develop proliferative 
retinopathy - formation of 
new blood vessels, which are 
especially leaky - in the eye. 
But there's never been an ani­
mal model in which you could 
duplicate thi s phenomenon. 
And it's been difficult to show 
permeability changes in the 
blood vessels, or structural 
changes. 
"There are an incredible 
number of metabolic and hor­
monal imbalances in diabe­
tics," Williamson continues, 
"and if you don't have some 
identical functional equivalent 
in an animal model, then it's 
virtually impossible to sort out 
which are important and which 
aren't. We dec ided to look at 
the role of sorbitol metabol ism 
with thi s model. We tested the 
ARIs and found that they com­
pletely prevented the increase 
in vascular permeabil ity." 
Another contributing factor 
to diabetes-induced complica­
tions appears to be sex hor­
mones. Pre-pubertal children, 
even those with poorly control­
led blood sugar levels, are 
spared diabetes' side effects 
until after puberty. 
Williamson was puzzled 
about how to reconcile these 
data until he remembered that 
the sorbitol-creating enzyme 
was first discovered in the male 
reproductive tract. "It's reason­
able that this enzyme would be 
modulated by sex steroids, 
particularly androgens such as 
testosterone," he says. "This 
may explain why chjldren are 
spared the complications of 
diabetes and suggests that tight 
Joseph Williamson induces new blood vessels to form in rats by 
slipping a piece ofpolyester fabric under the skin. The polyester 
fibers plus collagenfibersform aframeworkfor new vessels, 
which here appear as circles. Using this technique, Williamson 








blood sugar control may not be 
so critical before pUberty. After 
puberty, ARls may be particu­
larly useful in preventing 
complications. " 
In preliminary tests, Tolres­
tat has not caused worrisome 
side effects, but Sorbinil has 
been implicated in serious 
reactions in a few persons. To 
Williamson, this means that 
care needs to be exercised, just 
as with any drug. "Some per­
sons can't take a common phar­
macologic agent like aspirin, 
either, but it doesn't mean it 
shouldn't be used . It just means 
that we have to use caution, 
just as we do with any drug 
that's potentially risky." 
Charles Kilo, M.D. '59, clin­
ical associate professor of med­
icine at Washington University, 
is cooperating in ARl clinical 
trials being conducted at 
Barnes and Children's hos­
pitals. He heads the Kilo 
Foundation, which supports 
Williamson's research among 
nearly 20 projects annually 
funded from its $600,000 
budget. 
"An animal model such 
as the one developed by Dr. 
Williamson, exhibiting 
changes similar to what goes 
on in humans, is a big step for­
ward in testing hypotheses 
about the mechanism of blood 
vessel and nerve injury," says 
Kilo. "And the aldose reduc­
tase inhibitors could be the 
miracle for the diabetic popula­
tion that insulin's introduction 
was in 1921. If they delay or 
prevent blood vessel and nerve 
damage, there is the potential 
to greatly reduce the severity of 
disease in the eye, nerves and 
kidneys. This could mean a 
savings of about $[0 million 






$:uumo h,. ',~( 
B(·~("ar.. h 
B ernard Becker, M.D., professor and head of the Department of 
Ophthalmology, has received a 
$30,000 grant from Research 
to Prevent Blindness (RPB), a 
voluntary organization com­
mitted to the financial support 
of eye research. 
The award is part of an over­
all 20 percent increase in 
RPB's nationwide support of 
eye research, Becker notes, and 
comes at a time when federal 
budget cuts are causing con­
cern for the continuity of medi ­
cal research . During the past 
27 years, the Department of 
Ophthalmology has received 
$293,900 in RPB funds. ''The 
significance of these grants 
cannot be overstated," Becker 
said . "They provide scientific 
freedom, and their impact is 
felt at every level of oUI re­
search program." 
Washington University has 
one of the world's largest re­
search programs devoted to 
ophthalmology and visual 
science. On-going research 
projects include studies of 
glaucoma, ocular manifesta­
tions of diabetes, abnormal 
retinal biochemistry and other 
eye di seases. The university is 
one of more than 50 medical 
institutions across the country 
whose eye research programs 
are assisted by annual grants 
from RPB. • 
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technique that disarms 
a pathogenic fungus 
may open the door to 
vaccines against disease­
causing microorganisms that 
change form when they enter 
the body. 
A team of researchers from 
the Medical Mycology Center 
reported recently in Science 
that a chemical called PCMS* 
prevents the thread-shaped His­
/oplnsma capsulalUm from 
changing into single-cell 
yeasts. The fungus causes his­
toplasmosis, a respiratory in­
fection that strikes an estimated 
500,000 Midwesterners each 
year. It normally changes shape 
when its threads - mycelia ­
move from soil as dust into the 
warmer environment of the 
lungs. 
Since only the yeast form 
causes disease, PCMS renders 
the fungus innocuous. But it 
doesn't prevent it from provok­
ing an immune response. 
Therefore, inoculations of 
chemically treated mycelia pro­
tect against future infections 
with virulent H. capsulalUm, at 
least in mice, the subjects of 
the Washington University ex­
periments. 
PCMS changes H. capsula­
tum permanently, affecting 
both the treated cells and their 
progeny, presumably by alter­
ing a gene that directs some 
crucial stage in the mycelium­
to-yeast transition . "We don't 
know the mechanism , but we 
are following up on that," says 
Gerald Medoff, M.D. , profes­
sor of medicine and head of the 
division of infectious diseases. 
" If the transition depended on a 
plasmid - an extra-chromo­
somal piece of DNA - and 
PCMS eliminated that plasmid, 
that might be one mechanism. 
Or PCMS might cause a chro­
mosome to rearrange i tsel f." 
The altered fungus itself 
probably will not become a 
vaccine because inoculation 
against the usually benign his­
toplasmosis seems unneces­
sary. However, it could serve as 
a model in the development of 
other vaccines. ''There are 
many parasites, such as the 
protozoan that causes malaria, 
that have a phase in a vector, 
such as a mosquito, and then 
convert to another phase when 
they affect humans. So if one 
could prevent conversion from 
one phase to another, it might 
be analogous to what we saw 





Shirley Sahrmann shows runner Jennifer Shifrin how to properly 
perform lower abdominal exercises. 
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Shirley Sahrmann, Ph .D., associate director for re­search for the program 
in physical therapy and assis­
tant professor in neurology and 
physical therapy, has received 
three of the country's foremost 
honors in physical therapy. 
The American Physical 
Sahrmann to receive the 
Mari an Williams Award for 
Research in Physical Therapy, 
and also named her a Catherine 
Worthingham Fellow. The Uni­
versity of Southern California's 
physical therapy department 
chose Sahrmann to deliver its 
1986 Viola Robins Lecture. 
The Marian Williams Award 
cites Sahrmann for leadership 
in physical therapy research, 
and for contributions that have 
helped bridge the gap between 
animal and human research in 
the neurosciences. 
Sahrmann is one of only six 
recipients of the award, first 
presented in 1965 to recognize 
individuals who have per­
formed sustained and out­
standing basic, clinical andlor 
educational research pertaining 
to physical therapy. The award 
commemorates Marian Wil­
liams, Ph.D., whose profes­
sionallife was dedicated to the 
promotion of physical therapy 
through teaChing, writing and 
research. 
The APTA's selection of 
Sahrmann as a Catherine 
Worthingham Fellow recog­
nizes her for national leader­
ship in advancing the science, 
education and clinical practice 
of physical therapy. The fellow­
ship was first awarded to for­
mer APTA president Catherine 
Worthingham in 1982. 
Sahrmann is the second dis­
tinguished health sc ientist to be 
chosen as Viola Robins Lec­
turer at the University of 
Southern California. Viola 
Robins had served as director 
of the department and asso­
ciate clinical professor of phys­
ical therapy. In her lecture, 
Sahrmann addressed classifica­
tion, the categorizing of 
patients by specific muscle im­
balance problems in order to 
ensure more effective therapy. 
Sahrmann first joined Wash­
ington University in 1959 as a 
staff physical therapist at the 
School of Medicine's Irene 
Walter Johnson Rehabilitation 
Institute. In addition to her cur­
rent appointments, she serves 
as an instructor in physiology 
at the School of Medicine. She 
received doctoral and master 's 
degrees in neurobiology, as 
well as a bachelor's degree in 
physical therapy, from Wash­
ington University. • 
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"Neural Regenera­
tion: Bridging the 
Gaps," a feature in 
the Fall 1984 issue of Outlook, 
described Washington Univer­
sity scientists' research on why 
brain and spinal cord nerve 
cells fail to repair themselves 
after injury. One area being 
investigated by Gerald 
Fischbach's group concerns the 
growing nerve tip and its influ­
ences on the muscle it inner­
vates. They know that where 
the nerve touches the muscle, 
clusters of acetylcholine recep­
tors assemble. (These receptors 
enable the muscle to respond to . . 
the neurotransmitter acetyl­
choline by contracting.) But 
they didn't know whether the 
receptor clustering was due to 
formation of new receptors, or 
whether the nerve caused pre­
existing receptors to migrate. 
Because of some recent 
evidence gathered by David 
Harris, Fischbach suspects that 
the nerve tip causes new recep­
tor subunits to be synthesized: 
"The receptor molecule is very 
complex," explains Fischbach. 
"It's made up of four subunits. 
David has been using recom­
binant DNA probes to measure 
the capacity of the muscle to 
synthesize receptor subunits. 
Our preliminary data suggests 
that that's probably increased, 
an effect of the growing nerve 
tip on the muscle." 
Postdoctoral fellow Lorna 
Role and predoctoral student 
Richard O'Brien found that 
nerve has a powerful effect on 
muscle: Receptor clusters on 
the muscle are within a few 













microns of the growing nerve 
tip. Says Fischbach : "That's a 
very high incidence. If you 
look anywhere else along the 
course of the nerve, the inci ­
dence is much lower. And that 
leads us to believe that there's 
something very special about 
the advancing nerve tip." 
Another former student, Ted 
Usdin , scored an impressive 
coup. He was able to purify 
a glycoprotein - a sugar­
containing protein - from ex­
trac ts of chick brain . Using a 
protocol developed several 
years ago, Usdin added several 
new purification steps "and 
ended up with a molecule 
purified to homogeneity," says 
Fischbach, "about a million­
fold purification, which is a tre­
mendous feat. Ted found that 
when this glycoprotein was 




ture, it promoted the formation 
of receptor clusters. " 
Now, the question to be 
answered is, is this molecule 
what growing nerve tips 
secrete to induce the receptor 
clusters? Postdoctoral fellow 
Doug Falls hopes to answer 
this question by making anti­
bod ies to the glycoprotein . 
"Once we have antibodies," 
says Fischbach, " we' ll see if 
the glycoprotein is located 
in the growing nerve tip and 
if we can use them to block 
its effec ts." 
Answers to such questions 
may prove a boon to clinic ians 
trying to treat patients with de­
vastating neurologica l condi­
tions such as myasthenia gravis 
or Alzheimer's disease. 
'There's a long list of possible 
causes of a disorder like 
Alzheimer's di sease," explai ns 
Leonard Berg, M.D. , director 
of the Alzheimer 's Disease Re­
sea rch Center at Washington 
Univer,ity. "We don't have 
enough background informa­
tion to narrow the li st and 
focus on (lne or two possible 
causes. 
" It 's sensible to look for 
ways brain cell s handle injury 
and adapt to survive and main­
tain function. And it's logical 
to assume th at brain cells will 
fall back to the basic mecha­
ni sms of growth and develop­
ment. Hopefull y, those basic 
biologica l principles can be 
studied in relation to a disease 
like Al zheimer's, to give us 
some means of palliating the 
disorder and reducing symp­
toms until the future, when 
we find a cure. " 
Gerald Fischbach, M.D. , is 






The layer of cells lining blood vessels plays a key role in repair and 
disease processes. The endo­
thelium, as it's called, consists 
of a single layer of ce ll s which, 
under normal conditions, stays 
smooth . Any roughness or 
irregul arity attracts blood com­
ponents that lead to the forma­
tion of clots. 
Yet when blood vessels give 
off new branches or repair 
themselves, these lining cell s 
must divide. And in diseases 
such as atherosclerosis, what­
ever keeps these lining cells a 
smooth layer stops working or 
is overpowered with the devel­
opment of an atheroma - a 
mass inside the blood vessel 
that becomes calcified over 
time, eventually blocking it. 
Researchers have been 
struggling for years to lea rn 
how blood vessels repair them­
selves and grow, and how these 
normal processes go awry 
when conditions like athero­
mas occur. Now, thanks 
to research performed at Wash­
ington University, there are 
some clues. 
Thomas Deuel's group has 
found a new protein in en­
dothelial cells. This protein is 
kin to one on which Deuel has 
worked for years, a protein 
called platelet-derived growth 
factor (PDGF). When sec reted 
into blood, PDGF attracts 
blood cells and other blood 
components to the area , and it 
stimulates cell divi sion. 
The new protein, which is 
structurally simil ar to one of 
the polypeptide chains com­
prising PDGF, is manufactured 
A microscopic view ofa chick neuron (righJ) and a muscle fiber (leli) in culture. A process has grown 
out of the body ofthe neuron andforkRd over thefiber.lnformatwn, ill theform ofchemical signals, 
can pass betweell the two cells at such contm:ts, which are called synapses. 
5 
c 
Atheromas, like the one in this drawing, form after the disruption 
ofnormal processes thal repair the linings ofblood vessels. 
by the same gene coding for 
PDGF molecules, report Deuel 
et al. in a recent issue of 
Science, Furthermore, Deuel 
discovered that this new pro­
tein could be found in much 
higher levels in actively divid­
ing endothelial cells but not in 
non-dividing cells. Thus, it 
may playa key role in normal 
repai r processes, and it may be 
implicated in diseases like 
atherosclerosis. 
"The gene for this PDGF­
like protein has been cloned," 
says Deuel, professor of medi­
cine and biological chemistry 
and director of hematology/on­
cology, "and we have cloned a 
piece of the gene from en­
dothelial cells. We have also 
developed antibodies to the 
protein. With antibodies and 
the DNA probe, we hope to go 
back and see under what condi­
tions the gene is expressed." 
Using the protein-specific an­
tibodies and the DNA probe, 
Deuel's team will examine le­
sions in the blood vessel wall 
and try to correlate anatomical 
changes with the presence of 
the protein. 
'There seems to be a sort of 
cascade of events that occurs in 
endothelial cells," summarizes 
Deuel, M.D., director of the 
Marilyn Fixman Cancer Center 
at Jewish Hospital. "On the one 
hand, these events should lead 
to a normal regeneration or re­
pair of blood vessels that have 
been injured. On the other 
hand, in tumor growth or ath­
erosclerosi s, those events are 
exaggerated or not under the 
usual regulation and thus con­
tribute to the abnormal situa­
tion. But how? That's the 
question we're trying to 
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HI' Elwin Sill iih 
he Division of Urologic 
Surgery has dedicated 
its library in honor of 
Elwin R. Smith and the 
Urologic Research Foundation . 
Smith, a St. Louis insurance 
executive, established the 
Urologic Research Foundation 
in 1979 to encourage and sus­
tain research in urologic disor­
ders. Since its beginning, the 
non-profit organization has 
raised almost a half million 
dollars, primarily through pri­
vate individual sources. 
'The Division of Urologic 
Surgery owes a great deal of 
gratitude to the organizers and 
supporting members of the 
Urologic Research Founda­
tion," says William 1. Cata­
lona, M.D., professor and chief 
of the Division of Urologic Sur­
gery. "At a time when gov­
ernmental funding of medical 
research has been reduced 
across the board, funding for 
research in urology has been 
stripped to the bone. 
"We have been touched by 
the tremendous support we 
have received from Elwin R. 
Smith and the other founders 
and members of the founda­
tion," he adds. "We dedicate 
our new library to Mr. Smith 
and the Urologic Research 
Foundation in recognition of 
their efforts on our behalf. We 
are delighted to honor them in 
this small way." 
Smith, who has been presi­
dent of the Urologic Research 
Foundation since its creation, 
of the board. Arnold Schwab is 
the new president. 
Smith 's association with 
Washington University began 
in 1920 when he was a student 
in the business school. He 
graduated in 1924 and received 
his master's degree in econom­
ics in 1926, the same year he 
formed the Smith Insurance 
Agency. He continues to be 
involved in the insurance busi­
ness with the firm Lawton­
Byrne-Bruner. ­
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Richard P Bunge, M.D., professor of anatomy and neurobiology, will 
conduct research for the next 
seven years with more than 
$900,000 in funding from a 
Javits Neuroscience Inves­
tigator Award. 
Bunge is the ninth Washing­
ton University faculty member 
to receive a lavits Award since 
the highly competitive awards 
program began in October 
1983. Award recipients are se­
lected three times each year. 
The U.S. Congress gives the 
awards in honor of Sen. Jacob 
-
K. Javits of New York, on rec­
ommendation of the National 
Advisory Neurological and 
Communicative Disorders and 
Stroke Council of the National 
Institutes of Health . Javits was 
a victim of amyotrophic lateral 
sclerosis (ALS), more com­
monly known as Lou Gehrig's 
answer." • was recently named chairman 
6 
L 
disease. ALS is a degenerative 
neuromuscular di sorder that 
attacks the nerve cells that 
control muscles. 
The Javits Awards, given to 
investigators who have submit­
ted regular research grant 
applications for competitive re­
view, encourage research and 
research training in commu­
nicative and neurological disor­
ders. The prestigious grants 
provide a seven-year com­
mitment of support to the 
researchers who receive them. 
Bunge is Beaumont-May In­
stitute of Neurology SCDoiar in 
Anatomy at the School of 
Medicine. His grant will allow 
detailed studies of the biology 
of the Schwann cell , the pre­
dominant helper-cell to the 
nerve fibers of the peripheral 
nervous system. The respon­
sibilities of the Schwann cell 
include production of myelin, 
the insulating material of 
peripheral nerve fibers, and 
production of extracellular 
matrix materials. The Schwann 
cell is affected in several 
human diseases, including 
neurofibromatosis and Guil­
lain-Barre syndrome, and is 
believed to be a key cell in 
fostering peripheral nerve 
regeneration. • 
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J R'geo Thorn'''. M.D. 
assistant professor of 
• otolaryngology, is one of 
40 outstanding American pro­
fessionals named to Group VII 
of the WK. Kellogg Founda­
tion's Kellogg National Fellow­
ship Program. 
The Kellogg program pro­
vides each fellow with a three-
year, $30,000 grant that fund s 
a study project outside the fel­
low's field of expertise. The 
foundation also will host edu­
cational programs in the United 
States and Latin America for 
the fellows. Group Vll mem­
bers will address leadership de­
velopment, focusing on such 
issues as the changing Ameri­
can family, agricultural and 
environmental resources for 
the future, and international 
interdependence. 
Thomas is on staff at Barnes 
and Jewish hospitals, sponsor­
ing institutions of the Washing­
ton University Medical Center. 
Before joining the Washington 
University faculty in 1983, he 
was clinical assistant professor 
of otolaryngological surgery at 
the University of Missouri 
Medical Center. 
He received the doctor of 
medicine degree from the Uni­
versity of Missouri School of 
Medicine in 1972. Thomas 
trained in surgery at Yale Uni ­
versity and in otolaryngology 
at the University of Missouri 
School of Medicine, and also 
completed a fellowship in 
facial plastic surgery at North­
western University School of 
Medicine. 
He is currently vice presi­
dent of the American Academy 
of Fac ial Plastic and Recon­
structive Surgery. He is also a 
member of the American 
Academy of Otolaryngology-
Head and Neck Surgery, the 
.,~ 
::lAmerican Board of Otolaryn- .,'" 
gology, the American College :r: 
c 
of Surgeons, the American ..c 
.Q 
Medical Association's Com­
miuee on the Young Physician, 
and the St. Louis Metropolitan 
Medica l Society • 
Bke . 'anwd P("W 
S(~hohll" in .h(~ 
Biollwd i.·al 
Sd('Jl(·t·~ 
Charles M. Rice, Ph .D., virologist and assistant professor of microbiol­
ogy and immunology, has been 
chosen as one of 20 Pew Schol­
ars in the Biomedical Sciences 
by the Pew Memorial Trust of 
Philadelphia . 
The 1986 Pew Scholars, 
junior faculty members at 17 
medical schools and research 
institutes in the United States, 
were selected in recognition of 
their promising work in basic 
science or clinical research. 
Each of the scholars will re­
cei ve a total of $200,000 over 
the next four years to encour­
age resea rch for the advance­
ment of human health. 
Rice's work, much of it done 
while he was a fellow at the 
California Institute of Technol­
ogy in Pasadena , uses recom­
binant DNA technology to 
unravel the molecular details of 
how viruses reproduce. This 
technology opens up new 
avenues for the design and 
propagation of live vaccine 
strains against RNA viruses, 
including yellow fever virus, 
Rice explains. Also, he says, it 
should allow researchers to ex­
plore the possible use of these 
viruses as transmitters for the 
cytoplasmic expression of 
foreign genes in animal cells. 
The goal of the Pew Memo­
rial Trust is to establish a 
network of outstanding, in­
novative researchers who are 
Ii.kely to become future leaders 
in the scientific community 
The Pew Scholars Program is 
administered at Yale University 
School of Medicine, and win­
ners are selected by a 13-mem­
ber national committee. 
Rice joined the Washington 
University faculty earlier this 
year. He recei ved a Ph. D. in 
biochemistry from the Califor­
nia Institute of Technology in 
1981. • 
Sindbis viruses, one type ofRNA virus that Rice is studying, bud 
through the outer membrane ofa chick embryo fibroblnst cell. 
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CVS: Reborn Partner In 

BY TONY DIMARTINO 
A fter deciding that there must be more to life than an MBA and a walletful of platinum credit cards, 
Nina - well-established in her career at 37 
- is pregnant for the first time. There's a 
one-in-IOO chance that her child will be 
born with a birth defect. 
Liane lost her first child three years ago 
to Tay-Sachs, a fatal brain disease. She's 
now eagerly expecting her second child. 
But there's a one-in-four chance that thi s 
baby will also be born with Tay-Sachs. 
Nina's age and Liane's genetic history 
mark their pregnancies as high ri sk. Both 
women are worried about their unborn chil­
dren: are they developing normally, or do 
they have genetic deformities that will cau se 
severe birth defects, impaired quality of life, 
or even death? 
Currently, many high-risk mothers-to-be 
wait anxiously until disorders in their un­
born children can be detected with amnio­
centesis. This prenatal diagnostic test 
analyzes cells from the fluid surrounding 
the fetu s. Amniocentesis can identify many 
birth defects, but cannot be performed until 
enough amniotic fluid has formed - at 
least the 15th week. Results may take two 
more weeks while the siphoned cells multi­
ply into a sample large enough to study 
But with an experimental screening 
procedure called CVS -chorionic villus 
sampling - being tested at the School of 
Medicine, results of cell analysis can be ob­
tained as early as the ninth week of preg­
nancy That 's at least six weeks earlier than 
amniocentesis. 
"The overwhelming advantage of 
CVS over amnio is early diagnosis," says 
James P Crane, M. D., director of the 
genetics division in Washington University's 
obstetrics and gynecology department. "If 
no birth defect is found, CVS provides 
earlier reassurance to frightened parents 
who might have considered ending the 
pregnancy. " 
[f a problem is diagnosed, Crane says, 
CVS allows parents more time to prepare 
for a handicapped child or, if the defect is 
severe, to end the pregnancy much earlier. 
"Early termination is safer for the mother 
both physically and psychologically," ex­
plains Crane, who also serves as director of 
obstetrics and gynecology at Jewi sh Hospi­
tal. "And first trimester detection of 
abnormalities also paves the way for fetal 
therapy, which may one day enable us to 
treat and correct defects before birth ." 
Fourteen other U.S. medical centers are 
examining CVS' safety and reliability under 
a Food and Drug Administration protocol. 
[n March, Washington University made the 
first national presentation of preliminary 
CVS evaluation results. The study was 
described in a poster session at a meeting 
of the Society for Gynecological Investiga­
tion in Toronto. 
The researchers attempted to assess the 
safety of CVS by comparing first trimester 
miscarriage rates in 116 high-ri sk women 
who underwent CVS to miscarriage rates in 
75 high-risk women who did not have CVS. 
There was one miscarriage among the 
controls and two among the CVS group. 
"One [CVS] miscarriage was due to a weak 
cervix that dilated prematurely, totally unre­
lated to the CVS procedure," says Crane. 
'The other case is still under investigation." 
Crane's group concluded that CVS did 
not significantly increase ri sk of mis­
carriage. "We've now done almost 200 
CVS procedures," says Crane. " We've had 
four more misca rriages since the meeting in 
Toronto, but none of them appears to be 
procedure-related. CVS is potentially as 
safe as amnio." 
The recent study did not compare amnio 
and CVS head-to-head, but data available 
worldwide shows that CVS seems safe. 
Crane cautions that no definitive compari­
sons can be made until many more CVS 
procedures - perhaps 30,000 to 40,000 ­
are completed. Statistics are being collected 
at the 15 U.S. centers and others abroad as 
the CVS evaluation continues. 
"So far, our diagnoses have been 99 per­
cent accurate, and there's every indication 
that CVS will eventually prove to be as reli­
able as amniocentesis," says Heidi Beaver, 
M.PH., a genetics associate. "We're just 
waiting for more patients to be referred so 
more diagnoses can be attempted. ,. 
Amniocentesis can identify about 200 
abnormalities. CVS currently can detect 
about 100 di sorders, but the procedure's 
diagnostic range could increase. 
Even so, CVS will never completely 
replace amniocentesis because it can't de­
tect neural tube defects - spina bifida and 
other spinal column disorders, which are in­
dicated by high levels of alpha-fetal protein 
in the amniotic fluid. Also, some uteri are 
positioned in such a way as to make it 
difficult to obtain an adequate sample of 
villus tissue. 
CVS, performed at Jewish Hospital, takes 






thesia and costs about $750, roughly the 
same as amniocentesis. "Like amnio, CYS 
" is relatively painless," Beaver explains. "In II < terms of discomfort , I'd compare amnio to a 
I blood test and CYS to a Pap smear." 
The CYS procedure begins with an ultra­
r sound examination to determine the em­
bryo's location and age. A thin, flexible 
catheter is guided through the cervix to an 
area between the uterine lining and the 
chorion - a layer of tissue that surrounds 
the embryo and eventually becomes the 
placenta. A syringe is attached to the cathe­
ter, and a sample of chorionic villi - tiny, 
hairlike projections - is withdrawn. 
About one one-thousandth of the chorion 
is removed. 
These cells can be examined almost 
immediately. Not so with amniocentesis. 
Collected through a hollow needle inserted 
through the abdominal wall into the amnio­
tic sac containing the fetus, fetal cells are so 
scarce in the amniotic fluid that they must 
multiply for at least two weeks in laboratory 
cultures. The delay means that amniocen­
tesis results often are not known until after 
the 20th week of pregnancy, well into the 
second trimester. 
Genetics associate Beaver says CYS will 
remain experimental until more centers pre­
sent their studies and the FDA is sati sfied 
that use of CYS catheters is safe. 
At least four different catheters are being 
tested, says Lillian Yin, Ph.D., director of 
the FDA's Office of Device Evaluation. 
"It is hard for us to estimate when CYS will 
be available to the general public. Research 
centers are sending their statistics on fetal 
loss to the catheter companies, which in 
turn will send them to us for review when 
enough data has been compiled." 
Both amniocentesis and CYS are con­
sidered invasive procedures and pose a risk 
of complications that might lead to mis­
carriage. They are recommended only 
when women will be 35 or older at the time 
of delivery; when women have had a previ­
ous child with a chromosome abnormality 
such as Down syndrome; or when women 
or their mates are carriers of a chromosome 
translocation, a sex-linked disease such as 
hemophilia or muscular dystrophy, or a 
biochemical di sease such as Tay-Sachs. 
CYS isn't new. In the late 1960s, about 
the same time amniocentesis was being de­
veloped, Scandinavian researchers showed 
that chorionic villus tissue could be used for 
prenatal diagnosis. But the miscarriage rate 
was high at that time, and the procedure 
was overshadowed by the early success of 
amniocentesis. 
It wasn't until the early 1980s that CYS 
- improved by refined ultrasound tech­
niques and availability of thin catheters that 
made cervical dilation unnecessa ry ­
began to catch on. The procedure was 
championed by British and Italian research­
ers and sponsored in the United States by 
investigators at Jefferson Medical College in 
Philadelphia, the University of California at 
San Francisco, Michael Reese Hospital in 
Chicago, and the Washington University 
team in SI. Louis. 
Within the next 10 to 15 years, experts 
predict that first-trimester CYS will enable 
doctors to diagnose potentially fatal birth 
defects early enough to treat them before 
birth. Many genetic disorders are caused by 
Using a dissecting microscope, research 
technician Nanette Fyan separates chori­
onic villus ti.ssue from matemal tissue. The 
villus tissue is cultured ovemight to gener­
ate cells for chromosome analysis. Sau Wai 
Cheung, Ph.D., standing, is the director of 
the cytogenetics laboratory at Bames 
Hospital, where the cells are prepared and 
analyzed. Results ofchorionic villus sam­
pling can indicate the presence or absence 
ofcertain birth defects as early as the ninth 
week ofpregna.ncy. 
a lack of some vital enzyme or substance. 
In Tay-Sachs disease, for example, an 
enzyme deficiency causes the abnormal ac­
cumulation of fatty substances in brain 
cells. By the second trimester, when amnio­
centesis finally diagnoses Tay-Sachs, brain 
damage has already occurred. "Early warn­
ing that all is not well within the fetus may 
eventually lead to treatment that will com­
pensate for any dangerous excesses or 
deficiencies," says Crane. 
Experts predict, however, thatCYS will 
raise as many questions as it answers and 
pose hard ethical choices. Although the ulti­
mate aim of early genetic screening is fetal 
therapy, ability to discover problems cur­
rently outstrips ability to solve them and 
may continue to do so for many years. In­
terpreting genetic messages adds fuel to the 
abortion debate. 
"We're not pro-abortion," says Crane. 
"But many high-risk parents who've experi­
enced the agony of watching their helpless 
child suffer and die will tell you that they'd 




Technology and Technique 
BY SUZANNE HAGAN 
T he matchbook-sized clear plastic device looked like a miniature Pachinko machine. But Kim Walton wasn't playing games. Instead, Walton - a technician in the 
clinical chemistry lab at Barnes Hospital- was preparing to test 
a few drops of serum using a state-of-the-art machine called 
"Vision." 
Walton uses this Abbott Laboratory device to analyze either 
whole blood or serum. First, the sample is centrifuged through the 
Pachinko-like maze of the sample holder; then, at the appropriate 
location, a pre-measured reagent automatically mixes with the 
centrifuged sample. Depending on which reagent is packaged into 
the sample holder, Vision measures the concentration of blood­
borne substances like cholesterol, glucose and uric acid. Soon, 
technicians may use the personal-computer-sized device to assay 
10 
In the clinical clU!mistry lab at Barnes Hospital, Jay McDonald (standing) studies test results generated by medical technologist Robert 
Roggeman. Roggeman operates the Paralkl Analyzer, which performs 28 different tests and can malu! 7,800 analyses per day. This 
machine will soon be replaced by an even more sophisticatedpiece ofequipment. 
Left: The Vision System is a laboratory device that calculates andprints out the concentrations ofblood components, such as proteins or 
electrolytes. Just two drops ofblood from afinger prick are sufficient for each analysis. 
II 
..... 
blood concentrations of theo­
phylline and creatinine. And in 
the future, Vision will be able 10 
measure concentrations of drugs 
such as phenobarbital and 
phenytoin, as well as natural 
components like iron, calcium, 
albumin and bilirubin. 
The Pachinko-like sample 
holder isn't the only innovation 
in state-of-the-art equipment. 
The Kodak Company has cre­
ated a blood chemistry machine 
that uses samples applied to 
film disks. Technology is the 
watchword. 
Yet these days, it's not only 
samples that are bouncing 
around in search of equilibrium. 
Physicians are pulled in one 
direction by manufacturers tout­
ing the latest in "foolproof' 
technology to equip their office 
laboratories; in another by the 
knowledge that many laboratory 
tests should be done in a hospital 
or commercial setting outside 
the physician's private office; 




ing reimbursement policies for laboratory 
tests. 
Some experts point to this as evidence 
that current trends are leading away from 
centralized laboratory facilities and that 
more tests will be done in physicians' 
offices, at patients' bedsides, and at home. 
Others point to the fact that many promi­
nent teaching hospitals are only just begin­
ning a task that Barnes Hospital set about 17 
years ago: dissolving individual labs and 
moving them to one central facility, gaining 
efficiency as well as consistently strict 
quality control standards. 
"I think that there has been a lot of talk 
about decentralization of laboratory facili­
ties," admits Leonard Jarett, M.D. '62, 
Flexner Professor and chairman of the 
Department of Pathology and Laboratory 
Medicine at the University of Pennsylvania 
School of Medicine. "But the reality is not 
as great as the talk." 
Jarett says that this "trend" is mythical 
because of two basic reasons: the rigid 
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and the fact that there are few tests suitably 
easy to be done outside an accredited labo­
ratory. One exception, he says, is glucose 
monitoring: "Blood glucose is measured by 
diabetics who are highly motivated, they 
really want to take care of that blood 
chemistry equipment. And they get infor­
mation within an acceptable range to be 
able to make their decisions. Is it really 
highly accurate and precise? No. The 
instrument they're using is not as good 
as the ones in a clinical laboratory. But 
it's good enough for them to make sensible 
dec is ions. " 
Jarett speaks with authority. Winner of 
the Ernest Cotlove Award, given by the 
Academy of Clinical Laboratory Physicians 
and Scientists, he led the effort in 1969 to 
centralize Barnes Hospital's laboratory 
facilities. Only now, he says, are other 
major academic hospitals like Massachu­
setts General and Brigham and Women's 
following suit. Why? "Profit. DRGs are not 
reimbursing like they used to," says Jarett. 
"There used to be all these little fiefdoms, 
with people doing their own 
tests, and it was profitable. They 
can't do this now; the hospital 
loses money, and they don't run 
24 hours a day or abide by qual­
ity control. 
"My staff just ran an educa­
tional program for physicians 
who want to do their own labo­
ratory testing," he continues. 
"Even though it was well­
attended, most of the physicians 
walked out with the realization 
that they really didn't want to get 
into it, once they were told what 
the legislation in the state of 
Pennsylvania requires for quality 
control." 
But Pennsylvania is one of 
few states that have rigid quality 
control standards mandated by 
law. A bigger factor, some ex­
perts say, is the changing reim­
bursement pattern. Now the 
incentive is for private physi­
cians to perform tests in the 
office instead of sending them 
out. And added to this are the 
growing numbers of instruments 
that make many tests easy to perform. 
Which way should the private practitioner 
turn? 
M1SSINC LINK 
"One advantage of performing tests in 
the physician's office is that the person 
performing the test knows the patient and 
could relate the test result back to the patient 
better than we can," says Patrick Murray, 
Ph.D., associate professor of medicine and 
pathology at Washington University and 
codirector of microbiology in laboratory 
medicine. 'The same thing would apply to 
a patient who's performing a test at home 
to monitor glucose or detect organisms 
in urine. The patient might pick up a 
slight change that we would consider 
insignificant. 
"On the other hand, particularly for tests 
performed with instruments, you may be 
misled by the simplicity of the testing pro­
cedure. You may not know when that test is 
accurate unless the appropriate quality con­
trol tests are performed. With our volume 
" I • 
I 
I 	 ottests, wccan financially ju,tify running a 
large numbcr of quality control tests. In aI 
physician's office, whcrc maybc only eight 
or nine tests are pert(mned each day, it's 
very difficult to justify spending the money 
required for quality control." 
"Training in the elements of quality 
assurance and quality control is missing 
in most independent setups," says Jack 
Ladenson, Ph.D, professor of medicine and 
pathology, "and this is thc key weakness if 
untrained people are doing the work. It's 
not that you can't learn how to pipette or put 
a dipstick into a sample. But how do you 
know that what you're doing is working 
right? That requires some concepts of 
statistics and quality assurance, which 
I think is the real missing link in non­
hospital-based labs." 
Ladensen, who is president of the Ameri­
can Association for Clinical Chemistry and 
director of clinical chemistry in the division 
or laboratory medicine, points out that in 
a laboratory like Barnes ' , 10 to 30 percent 
of samples tested aren't from patients: 
in one way or another, they arc relatcd to 
assuring quality. 
"When you leave that out. evcntually 
you're asking for problems, " he points out. 
"We look at the tOlal picture of 'quality' ­
is the test being done accur<ltely, precisely, 
rapidly enough; is it the right test; should 
there be additional tests - thcse are the key 
components of the job we do." 
So it's this no-win situation that has many 
clinicians confused. Fortunately, a Physi­
cian Outreach Program is aV<lil<lble through 
Barnes Hospital. "This program is designed 
I'or us to help physicians in their otllce do as 
many tests as they can do well in their 
office, with our help and quality control ," 
says Jay M. McDonald. M. 0., professor of 
pathology and medicine and director of the 
division of I<lboratory medicine. "And we 
can hclp them determine what tests they 
shouldn't do. We will do them very compe­
titively. We can oller them other assistance 
because we have all the hospital information 
in one package and can transmit all kinds of 
information from the hospital to help them 
practice medicine, Our goal is not to do 
their work. but to help them do the work 
themselves and do il right." 
Laboratory medicine at Washington 
University is a clinical division that weds 
pathology to medicine; practitioners 
carry appointments in both departments. 
Within the scope of laboratory medicine, 
headed by Jay McDonald, are sections in 
microbiology, clinical chemistry, blood 
bank, hematologylhemostasis, and 
immunology/HLA (human lymphocyte 
antigens). 
What gives rise to a new academic 
specialty like laboratory medicine? 
According to Leonard Jarett, who was 
the nrst to head the new division at 
Washington University, the normal pro­
cess of instituting a new specialty 
worked backwards: "Typically, a spe­
cialty grows and becomes strong in the 
community because of what's at the 
medical school. Laboratory medicine 
went the other way - it started out in 
the community and then came back to 
the medical school. 
" At academic centers, internists. sur­
geons and others often did individual 
tests in their labs with no coordinated ef­
fort. They were not usually interested in 
Sample holders in tlu: Vision System, which separates whole bwod into cells and 
plasma and then m.i.x£s a correct amount ofplasma with reaKents. 
residency training, teaching. quality con­
trol or the consultative role that labora­
tory physicians and scientists now play 
Thus, at academic centers, laboratory 
medicine is distinct from anatomic 
pathology. Furthermore, laboratory 
medicine reflects a more academic and 
scholarly approach than that found in 
traditional clinical pathology. " 
Washington University was one of the 
first academic medical centers to estab­
lish a division of laboratory medicine. 
Jarett, who now chairs the Department 
of Pathology and Laboratory Medicine 
at the University of Pennsylvania, says 
that Washington University'S program in 
laboratory medicine " is unequivocally 
number one in the country." 
He says that nationally, laboratory 
medicine is in its " ... preteen period . 
Future developments in the neld will de­
pend on what happens in the medical 
centers in Boston and at Johns Hopkins. 
If those places develop strong academic 
programs, we will jump immediately 
from our preteen period to young 
adulthood." 
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Jack Ladenson has developed an a5say for an enzyme that appears in serum after a myocardial infarction. He uses monoclonal antibodies 
to measure the enzyme. Right: This cwse-up shows how the Paralwl Analyzer got its name. 
FlNE-TUNINC IHACNOSIS 
TypicaJly, private practitioners have 
office laboratories that perform microscopy 
and other tests. Many still send some of 
their tests out to commercial and hospital 
laboratories. Nevertheless. they want to do 
what can be done in-house to increase 
profits and speed turnaround time, yet 
they're aware that quality control could be a 
problem. So a Physician Outreach Service, 
such as the one provided by Barnes Hospi­
tal, is often just what the doctor ordered. 
One of the private practitioners who's 
found thi s service helpful is John William 
Campbell, M.D. '77. FHS, now a specialist 
in infectious di seases at the Grant Medical 
Clinic in St. Loui s. Campbell, who was 
chief resident in medicine, says that he 
occasionally comes across patients whose 
infections are difficult to diagnose. "Some­
times the culturing techniques may be diffi­
cult, or the blood tests fall into the gray 
zone of interpretation," says Campbell. 
Campbell says he plans to use the oui­
reach service to help train the Grant Clinic 
staff. which already has more training than 
is typical: One of the clinic's physicians' 
assistants has training in medical technol­
ogy. Says Campbell: "We do all the routine 
things most laboratories do - blood 
counts, sedimentation rates, urinalyses, 
blood potassium levels. But most of our cul­
turing is still sent out." 
But there are limitations to what such a 
consultancy can do, and the principal prob­
lem is that it's really the patient who tells the 
story, not the bodily fluids: "We're only 
consultants," McDonald says. "We can't 
palpate the abdomens, we can't look in the 
eyes, and we can't take the histories." 
Quality control isn't just an issue with 
private physicians doing their own tests, 
says McDonald. It's a major problem 
in many hospitals. too: "In some hospitals, 
there are untrained persons doing what 
seem like the simplest tests, and they're 
making errors. One of the things we're 
setting a priority on nationally is to make 
sure that the practice of laboratory testing 
does not deteriorate because untrained 
persons are performing tests." 
To alleviate this, McDonald is participat­
ing in a national task force that is looking at 
the problem of quality control in glucose 
monitoring. "How do you monitor glucose 
and do it effectively?" he muses. "That's the 
question we're trying to answer. Can it be 
done well by nurses, or do you need to limit 
the number of persons who do it? I don't 
think it has to be done necessarily by regis­
tered medical technologists; it just has 
to be done by persons who've been trained 
or retrained." 
The task force on glucose monitoring, 
organized by the American Diabetes Asso­
ciation, wil.1 result in a consensus report. 
McDonald says that the answers obtained 
here will help determine the way quality 
control issues for other types of such tests 
are handled: "You have to establish criteria 
for analytical excellence." 
Another group that establishes perfor­
mance standards for a wide range of labora­
tory tests is the NCCLS - National Com­
mittee for Clinical Laboratory Standards ­









Ladenson and others have1  . 
worked with manufacturers like~ -' Abbott and Ames to evaluate 
chemical analyzers' perfor­
mance. "In some cases," says 
Ladenson, "the machines per­
form well. In others, the pre­
cision is not what can be 
achieved in a laboratory like the 
one at Barnes. In many cases, it 
makes sense to do these mea­
surements in the physician's 
office, while the patient waits to 
find out if the medication they're 
on needs adjustment. The major 
drugs that can be monitored 
with in-office devices are 
theophylline, digoxin and the 
anti-convulsant drugs. So these 
are the tests most companies are 
trying to develop." 
Added to the push by manu­
facturers to sell physicians office 
laboratory equipment is the 
additional incentive to test in­
house because of the changing 
reimbursement pattern. If a 
clinician gets reimbursed by 
Medicare, for example, then the 
laboratory doing the test must be 
the laboratory that bills Medi­
care. "This is different than 
before," says Ladenson, "be­
cause then, a physician who 
collected a sample could bill 
Medicare for the test yet arrange 
for another laboratory to do it at 
a lower charge. Now, there's an economic 
incentive for clinicians to do these tests in 
their own offices, since the cost of perform­
ing the test is generally less than what 
Medicare will pay. 
The realm of home tests is also growing, 
and more manufacturers are trying to cash 
in on a lucrative market. But Murray, who 
chairs the Clinical Microbiology Division of 
the American Society for Microbiology, is 
skeptical of how useful to consumers many 
of these home tests will be: "I was at an 
FDA meeting in Washington recently," he 
says, "and saw a home diagnostic test for 
gonorrhea. What was especially disturbing 
to me was that this is a test being marketed 
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courage the patient from seeking 
necessary medical care." 
ADVANTACES OF 
ACADEME 
An academic entity like labo­
ratory medicine, born of a union 
between pathology and medicine, 
is more than machine monitor­
ing. In addition to the instruction 
all students receive in laboratory 
medicine, there is a vigorous re­
search program. The division 
currently has nearly $1.8 million 
in annual funding for 32 re­
search projects. 
Says Ladenson: "We are de­
veloping monoclonal antibodies 
for measurement of isoenzymes, 
which are the different forms of 
an enzyme. The reason we mon­
itor enzymes is usually to assess 
the extent of cell death. If we 
have specificity in that measure­
ment, then we can begin to 
make much better predictions of 
the cell or organ involved." 
Ladenson's research team is 
working on one of the enzymes, 
creatine kinase, that's a marker 
for cardiac cell death in myocar­
dial infarction. They have devel­
oped an assay specific for only 
the enzyme CK-MG, found pre­
dominantly in the heart. This 
assay is based on a unique 
monoclonal antibody they 
They are instructed to test their urethral 
exudate. and within seconds the test results 
are available. If the test is positive, the pack­
age insert recommends that they see a phy­
sician. But what the manufacturers neglect 
to say is that patients should also see a 
physician if the test is negative because 
urethritis is not normal. 
"I think. the real burden is on the FDA to 
determine which tests are really appropriate 
for home use. This particular test had al­
ready been licensed for males, and the com­
pany wanted to expand its use to females. In 
fact, it shouldn't have ever been licensed. 
It's not a precise indicator of the gonorrhea 
micro-organism, and a negative test result 
in a symptomatic patient should not dis-
developed that recognizes only the iso­
enzyme CK-MB among the three iso­
enzymes of creatine kinase known to exist. 
Besides being very precise diagnostic tools, 
these tests will help probe the mechanisms 
of these enzymes, thus adding to the fund of 
basic science knowledge. 
But this research is only one aspect of 
what laboratory medicine is all about: 
"We have to dispel the notion that the 
laboratory is a black box," says Ladenson, 
"where you put a sample in, a number 
comes out, and the whole process works 
through some sort of miracle. Without 
knowledge of the process, you're just 
pushing a lot of numbers. And that's not 
information, it's just data." 
15 
Jtarming up to 
Uhiquitin 
BY 
The gender of our offspring is not protect cells and enhance their survival Milton 1. Schlesinger, Ph .D. , was treating something we primates leave is unknown. cells with heat to see what new proteins _ ungoverned; sex chromosomes The effects of heat shock were first de­ might be induced. 
called "X" or "Y," nestled among the other scribed about 25 years ago. Exposure to Rather than looking at the new proteins 
22 in sperm , determine whether we buy heat produced marked changes in fruit fly themselves, she examined the messenger­
pink or blue booties. Some turtles and chromosomes. RNA that carries instructions for their 
li zards, however, do things differently. During the next 15 years, the phenome­ manufacture. 
The sex of their offspring depends solely on non was defined; new RNAs and new pro­ "When I started to analyze the m-RNA 
the temperature caressing their clutch of teins, called HSPs, were identified. Yet present in the cells after heat shock," says 
leathery eggs. For map turtles, very low the heat-induced changes in fruit flies were Bond , "I found several RNAs that were in­
(20 C) or high temperatures (31 C) induce thought to be an interesting but isolated duced. When I sequenced one of them, I 
-
femaleness; mid-range temperatures pro­ anomaly. But in the late 1970s, research in found it coded for ubiquitin. That was the 
duce male offspring. the fi eld of heat shock proteins took off. first time anybody had shown that ubiquitin 
Heat, then, could be considered sexy be­ When exposed to heat, cells of most organ­ was a heat shock protein. " 
cause of its strange and wonderful effec ts isms, rrom bacteria to humans, displayed Ubiquitin, a 76-amino acid protein, had 
on amphibians ' eggs. But the story doesn't these unusual proteins. first been described in 1975. Because of its 
stop there. Across the realm of biology­ Because their structure is identica l, or widespread distribution among species, 
from primitive, one-celled organi sms to nearly so, from one spec ies to another, and the fact that its amino ac id structure is 
complex creatures like amphibians, birds HSPs were believed to play an integral role nearly identica l from species to species, 
and mammal.s including humans -the in all cells. Yet their actual function ubiquitin was thought to play an important 
application of a stressor such as heat brings remained a mystery. role in cells. But just how important is only 
about profound changes within cell s. No one is sure how many HSPs exist, but beginn ing to be understood. 
Too much heat, of course, can be fatal to their number is probably small. In chicken "Ubiquitin is needed for all cells to go 
cell s, congealing their proteins into a useless cells, four major HSPs have been identified. through their cycle of cell division," says 
glob. Cancer cells seem to be particularly Three are known simply by their subunit Schlesinger, professor of microbiology and 
sensitive, which is why hyperthermia is part molecular weights: HSP-90, HSP-70 and inUlluno]ogy. "We think that ubiquitin's im­
of oncologists' armamentarium . But non­ HSP-24. But the fourth , ubiquitin (so named portance lies in its assoc iation with proteins 
fatal amounts of heat applied to normal because of its ubiquitous distribution from known as histones, which are molecules 
cells stimulate the production of what are spec ies to spec ies), wasn't even known to be that interact with DNA in a highly orga­
known as the heat shock proteins (HSPs). a heat shock protein until a few years ago. nized structure. It 's been known for many 
We don't know whether HSPs cause sexual Like so many important scientific dis­ years that about 15 percent of hi stones have 
differentiation in map turtles, ordaining that coveries, ubiquitin's identity as a heat shock ubiquitin attached to them. This attachment 
one clutch of eggs will be primarily female protein was serendipitous. Ursula Bond, a occurs only during a portion of the cell 




Predoctoral student Ursala Bond discovered that ubiquitinformaLion is induced as temper­
ature rises, mnking it a memher ofa still-mysterious famiLy ofproteins caLled heal slwck 
proteins. Ubiquitin was so named due to its presence in a wide variety ofspecies. 
divide, these ubiquitinated histones release 
their ubiquitin. Apparently, as soon as the 
ubiquitin is released from the histone, the 
chromatin condenses into a form that is 
ready for cell division." 
Besides its functions in the cell nucleus, 
ubiquitin plays a second role. It serves as a 
marker, tagging proteins that need to be 
broken down. "The way the system works," 
remarks Schlesinger, "is that there's a set of 
enzymes that recognize ubiquitin. In the 
presence of ATp, these enzymes can activate 
ubiquitin. The activated ubiquitin is then 
attached to proteins destined for disposal. 
A single protein can get many ubiquitin 
molecules attached to it." 
The remainder of this cellular protein­
digesting scheme is unknown in detail, says 
Schlesinger, but it too is dependent on ATP 
"Most cellular protein-digesting activities 
we're familiar with occur in compartments 
- there are protein-digesting enzymes on 
the membranes of the Golgi secretory sys­
tem, and in Iysosomes and mitochondria. 
But the ATP/ubiquitin system may be the 
only protein-digesting system present in the 
cytoplasmic part of cells. " 
In addition to its functions in ceU division 
and protein breakdown, ubiquitin has a 
third role: It has been found on "homing 
receptors." These are structures on the sur­
faces of lymphocytes enabling them to 
"home in on" and bind to tiny veins in the 
lymph organ from which they originated ­
their first "home." 
"We really don't know whether the 
ubiquitin found on these homing cell recep­
tors is acting as a modulator of the receptor 
structure," says Schlesinger. "It could be 
affecting the receptor's function, as it does 
for histones. Or if many molecules of 
ubiquitin are present, it could be a mecha­
nism for eliminating the receptor from the 
cell surface." 
Heat shock proteins like ubiquitin are 
produced in response to several forms of 
stress, including heat. In some way, the ap­
plication of this stress triggers the so-called 
"promoter" region that governs the activity 
of genes coding for the heat shock proteins. 
In fact, HSPs like ubiquitin have a unique 
promoter region , the so-caJled "Pelham 
box," named for its Cambridge discoverer, 
Hugh Pelham. 
"So there are two criteria that I consider 
for any heat shock protein." summarizes 
Schlesinger. "It is inducible after heat or 
some other stress is applied to cells. And its 
production is governed by the Pelham box 
promoter region." 
"We've shown that the gene coding for 
ubiquitin has all of the characteristics of a 
heat shock gene," says Bond. "It has the 
Pelham box. And you can see this gene 
expressed when you give the cell several 
forms of stress." 
Bond has just sequenced the gene for 
ubiquitin in chicken cells. This may be the 
first complete sequence of the gene for 
ubiquitin. 
" It's a very simple gene, made up of mul­
tiple copies of the protein-coding sequence 
placed in tandem to each other," says Bond. 
"And that makes it really unique. Also, it 
has an intron - an intervening sequence of 
base pairs, not part of the protein code-
at one end. That was a surprise because 
normally heat shock genes don 't contain 
introns. " 
The important roles played by HSPs gen­
erally, and ubiquitin in particular, are only 
just beginning to be understood. for the 
ways that HSPs help cells tolerate stress 
remain a mystery. 
"Shortly after we began studying HSPs," 
says Schlesinger with a grin, "a colleague 
warned that we might be ' hunting the 
snark.' r think that 's unlikely. There's plenty 
of evidence to indicate that we'JI soon know 
what heat shock proteins do." • 
Editor's Note: For further information, see 
"Ubiquitin Moves to the Cell Surface," 










BY LINDA SAGE 
Lorraine Luebbert ifCreve Coeur, Missouri, 
has a new lease on life. In July 1985, her doctor 
diagnosed kidney cancer and predicted death 
within two nwnths. But seeking a second opin­
ion, Lorraine had the kidney tumors removed 
and entered an experimental interferon pro­
gram at Washington University. She still has the 
cancer, in the form ifmetastatic growths on the 
pancreas. But she is still alive to enjoy her 
grandchildren. 
Corrine Durand of Galesburg, Illinois, 
doesn't have to look up the date of her son's 
first interferon treatment - December 19, 
1983, is engraved on her mind. In the previ­
ous six months, Michael had undergone 
laser surgery every two to three weeks for 
recurrent growths on the larynx. Each oper­
ation lasted over an hour and cost $3,500 to 
$4,000. But with regular injections of in­
terferon, the intervals between surgery 
lengthened and then the growths dis­
appeared. Michael is now a healthy 4-year­
old and has needed neither surgery nor 
interferon since June 1985. 
In clinical trials, there may be only a few 
such success stories, but each provides hope 
during the long hours of research that fol­
low. At Washington University, there is hope 
among clinicians who are testing the anti­
viral and antitumor properties of the in­
terferons, a family of proteins that have just 
become widely available. 
In the division of pediatric otolaryngol­
ogy, an interferon is on trial in the treatment 
of recurrent respiratory papillomatosis, the 
viral disease that afflicted Michael Durand. 
In the division of urologic surgery, urol­
ogists are testing two types of interferon 
against renal cell adenocarcinoma, the 
kidney cancer that has striken Lorraine 
Luebbert. And pediatric oncologists will 
see if an interferon can combat relapses of 
19 
the most common childhood leukemia, 
ac ute lymphoblastic leukemia. 
Papi Ilomas 
Recurrent respiratory papillomatosis 
(RRP) begins most often in children be­
tween the ages of 12-24 months, though it 
can occur at any age. Only 1,500 cases are 
diagnosed in the United States each year, 
but RRP can be devastating for those af­
fected . A carbon dioxide laser can safely re­
move most of the growth from the larynx, 
windpipe or nasa l part of the pharynx , but 
some infected tissue usually remains and 











cords, the first symptom is hoarseness. But Michael Durand with his mother, Corrine, at their home in Galesburg, Illinois. 
as it proliferates, like the top of a miniature 
cauliflower, it can completely close off the 
ai.rway - a tiny 5mm in diameter in a small 
child. Children need an average of 13 oper­
ations to clear them of the disease, but some 
patients make hundreds of trips to the 
operating room. And for parents, there is 
the constant worry about the timing of the 
surgery. 'The most traumatic thing is that 
you don't know how far [the disease] has 
gone," says Connie Durand. "You live on 
pins and needles." 
Inevitably, she and her husband once mis­
judged the extent of the papilloma. One 
night they found Michael bouncing in his 
crib as he struggled for air. He had devel­
oped stridor, the noisy respi.ration typical of 
a blocked airway, and he needed immediate 
surgery. 
Other than interferon , there is little help 
for patients like Michael. Radiation therapy 
is ineffective and may convert the benign 
growths into malignant tumors. Chemicals 
applied directly to the vocal cords and 
courses of antibiotics, steroids or chemo­
therapeutic agents (such as 5-fluorouracil) 
are also of little use. 
In 1978, a Swedish physician who was 
treating a woman with interferon for cervi­
cal cancer noted that the plantar warts on 
the woman's feet disappeared. Rea soning 
that plantar warts are closely related to 
laryngeal warts, he gave interferon to seven 
children with respi.ratory papillomas. In 
1981, he reported that most of the children I had improved dramatically. 
Clinical tri als began at Washington Uni­
versity in early 1982, when Harl an Muntz, 
l 
20 
M.D. ' 77, assistant professor of otolaryngol­
ogy and pediatrics, entered a study using in­
terferon provided by Burroughs WelJcome. 
In July 1985, assistant professor of otolaryn­
gology and pediatrics Rodney Lusk, M.D. , 
joined the Washington University staff, 
bringing experience of two other types of 
interferon under investigation. Lusk had 
previously participated in the study at the 
University of Iowa. 
The Burroughs Wellcome trial is one of 
two carefully controlled studies to assess 
the effectiveness of interferon against RRP 
It involved 66 patients who previously re­
qui.red laser surgery at least every two 
months. Twelve of the patients were from 
Washington University. 
The patients were divided into two age­
matched groups. After their last laser treat­
ment , half the patients were randomized 
into a six-month trial of interferon , and the 
other half continued to have laser treat­
ments. At the end of the six months, the two 
groups were crossed over. 
Only the data for the first six months 
have been analyzed. Among the 33 patients 
treated with interferon during that time 
period, three responded completely and 15 
had partial remissions, whereas none of the 
patients in the control group improved. 
Though heartened by these findings, 
Lusk is not ecstatic: "Interferon is not going 
to be a panacea for RRP," he says. " It is 
effective in some children but not in all. 
That may have something to do with the 
~ l 
type of virus since there are several sub­
types, some much more severe than others." 
At present , the Burroughs-WelJcome trial 
is expanding to include RRP patients who 
require surgery every three to nine months. 
"Since interferon seems to be effective in a 
certa in percentage of patients," says Muntz, 
"less severely affected ones may also bene­
fit. We'll be doing mostly adults becau se it's 
a problem for them to take off from work 
every few months to go to the hospital. And 
between times, they have significant hoarse­
ness and symptoms of airway obstruction." 
Kidney Cancer -I • 
Although RRP can be a major trauma, it 
is rarely fatal. Not so with renal cell 
adenocarci noma, which kills about 8,000 .. 
Americans each year, mostly men over 40. 
The on ly treatment is early detection and 
removal of the affected kidney. But diag­
nosis is rarely made in time because the dis­
ease is symptom-free in its early stages. If a 
tumor grows large enough to cause prob­
lems, metastases inevitably occur. Then, 
there is no effective treatment because the 
cancer is resistant to all forms of 
chemotherapy. · ( 
Previous studies showed that gamma in­
terferon has some activity against renal cell 
adenocarcinoma. For example, the protein 
inhibited the proliferation of kidney cancer 
cell s in tissue culture and slowed the growth 
of human kidney tumors transplanted into ·,. 
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about one-third of patients made some type 
of response to interferon. 
William Catalona, M.D., professor of 
surgery (urology), Timothy Ratliff, Ph.D., 
research associate professor of surgery 
(urology), and surgery resident M'liss 
Hudson , M.D., began to test gamma inter­
feron on 14 patients, including Lorraine 
Luebbert, in August 1985. Their studies 
were part of a Biogen trial with interferon 
produced by recombinant DNA technology. 
Of the 14 patients, six received only 
progesterone, the approved but largely 
ineffective treatment for renaLcell 
adenocarcinoma. The other eight received 
gamma interferon. CT scans at six-week in­
tervals revealed that three of the test patients 
had responded, though one later relapsed. 
(Failure of the tumors to grow larger was 
considered to be a response.) 
"There are two potential mechanisms of 
action," says Ratliff. "One is direct inhibi­
tion of cell growth by interferon. The other 
is interferon's ability to augment the im­
mune response. It activates cells that attack 
and kill tumor cells. It also enhances tumor 
cells' expression of proteins that the im­
mune cells recognize." 
Now CataJona , Ratliff and Hudson are 
taking part in a new multicenter study spon­
sored by Schering-Plough. The patients will 
receive gamma or alpha interferon alone or 
together. The hope is that the latter will be 
more effective. In tissue cultures of kidney 
cancer cells, the two interferons halve the 
rate of cell proliferation when combined at 
concentrations where neither is effective 
alone. The duo also decreases the growth of 
human kidney tumors implanted into mice. 
But Ratliff is tempering his optimism. 
'These drugs are just experimental ," he 
says. "We can't offer them to patients as 
treatment. We are just trying to develop 
new approaches for the use of interferons, 
and we hope that this study will provide us 
with better results than we have gotten in 
the past." 
Childhood Leukemia 
Unlike the struggle against kidney 
cancer, the fight against childhood leukemia 
has been one of the success stories of the 
last decade. Fifteen years ago, only 20 per­
cent of children with acute lymphoblastic 
ll 'hen alpha interferon was first de­
scribed in Britain in 1957, it was dubbed 
"imaginon" by scientists who doubted its 
existence. But today, we have tangible 
proof of its reality. Large quantities can 
be prepared, either from a line of abnor­
mal white cells or through recombinant 
DNA technology. Copies of interferon 
genes inserted into cultured cells such as 
bacteria make the cells push out high 
concentrations of the protein into the 
medium. 
The greater availability of the inter­
ferons has led to numerous clinical trials 
and, recently, to conunercial. availability. 
[n March, Britain's Committee on Safety 
in Medicines approved the sale of alpha 
interferon tor the treatment of hairy cell 
leukemia , an adult cancer. And in June, 
the Food and Drug Administration 
licensed Hoffman-LaRoche and Scher­
ing-Plough to sell alpha interferon in the 
United States for the same purpose. 
The interferons promise to treat a 
much wider range of conditions than 
hairy cell leukemia, however. Recent 
studies have shown that interferons can 
protect cultured cells from the AIDS 
virus, control genital warts and alleviate 
the pain and inflammation of rheumatoid 
arthritis. Moreover, nasal sprays of 
interferon halt the spread of rhino­
viruses, the most common of the 
common cold viruses. 
Neither the antiviral nor antitumor 
activities are fully understood. But in­
terferons are known to inhibit cell 
growth and cell division, modulate dif­
ferentiation and alter cell surfaces. 
They also activate part of the immune 
system. ­
leukemia (ALL) were alive five years after 
diagnosis. But thanks to new methods of 
chemotherapy developed in the mid-1970s, 
55 to 60 percent of the 2,000 new cases 
diagnosed in the United States each year 
survive for more than five years. And most 
of those patients are cured because relapses 
after four years are rare. 
However, the Pediatric Oncology Group, 
an organization of childhood cancer treat­
ment centers, is rooting for the 40 percent 
that succumb to ALL. At highest risk are 
black chi Idren and males of all races who 
are less than three years old and over six 
years old, have high white cell counts at ini­
tial diagnosis and rearranged or defective 
chromosomes in the abnormal white cel Is. 
If the cancer cells are derived from the pre­
cursors ofT-cells, which form in the thymus 
gland, the outlook is worse than for non-T­
cell leukemia. 
The pediatric oncologists will take part in 
a clinical trial funded partly by the National 
Cancer Institute. The study will determine 
if interferon can help children who relapse 
after chemotherapy and an initial remis­
sion. "If you have a cancer that relapses in 
spite of state-of-the-art therapy and high 
cure rate, you are in trouble," says Vita 
Land , M. D., associate professor of pediat­
rics and one of the five WaShington Univer­
sity pediatric oncologists involved in the 
study. "Then it becomes ethical to introduce 
a new therapy." 
The patients will receive seven days of 
alpha interferon treatment followed by stan­
dard chemotherapy. The latter usually 
brings a child into a second, temporary re­
mission , and interferon therapy will con­
tinue periodically during that time. 
Interferon is active against ALL cells in 
culture and in animals. Also, it has helped 
adults with ALL or a closely related cancer 
of the lymph glands. "However, children 
aren't necessarily little adults," cautions 
Land. "Just because interferon seems to 
have activity in adult leukemia doesn't mean 
that it will work in kids." 
Clinical trials with experimental drugs 
such as interferon are carefully evaluated by 
both federal and university personnel. The 
ALL protocol was approved by the Food 
and Drug Administration and the National 
Cancer Institute in March 1986 and by the 
Human Studies Committee of Washington 
University School of Medicine's Institu­
tional Review Board in May. If the therapy 
proves very effective, the next stage would 
be a controlled trial with newly diagnosed 
patients. So as with the RRP and kidney 
cancer trials, the verdict will not be in for a 









B Y CAN D ACE 0' CON NOR 
A s a promising biology student at chemistry, associate director of the division . '" St. Olaf College, Sarah Bronson and director of graduate training. "When hadn't quite decided whether she'd go we offer admission to top students, they 
on to graduate school. Then she spent last may instead choose Princeton, MIT or 
summer as one of 15 undergraduate re­ Stanford. The competition for the best stu­
search interns in Washington University's research internship, the aim is to attract top­ dents is now greater, so the percentage 
Division of Biology and Biomedical Sci­ notch students to Ph.D. and M.D.lPh.D. 
pences, and her summer experience resolved programs in the graduate division. And this 
Kathy Buchanan, a promising under­all her doubts. This fall, she's a brand-new effort has been extremely effective, yielding 
graduo.Je at Colorado College, Coloradopredoctoral student working in molecular a bumper crop of fine students like Sarah 
Springs, had the chance to test herselfinimmunology. Her early reaction to the pro­ Bronson. In recent years, for example, ap­
research and "a graduo.Je study atmo­gram? "It's even better than last summer," plications from small liberal arts schools 
sphere" during her summer work atshe says happily. - a special recruiting target - have in­
Washington University. EXi:ellent smallThis kind of success story is a tribute to creased five-fold. 
schools such as Colorado College have been • 0 Washington University's recruitment pro­ "The quality of our applicant pool is 
targeted by the School ofMedicine as agram, one of the most active among univer­ better than ever," says Carl Rhodes, Ph.D., 







we are able to enroll may not be as high. 
But in the end we will have better students." 
Reaching these students requires year­
round work by Rhodes, who heads the re­
cruitment effort, and his four-member staff. 
In late summer, they mail more than 
1,000 posters and brochures to every major 
biology and chemistry department in the 
country. Within weeks, Rhodes is airborne, 
visiting some 25 campuses. Each year, he 
adds new schools to his itinerary; last fall, 
he made his first stops at Bates, Bowdoin, 
Colby and Trinity (Texas). His goal is to 
meet students and cement ties with sym­
pathetic advisers, usually faculty members 
whose active research programs entice stu­
dents interested in graduate work. 
While most science faculty at these 
schools already know Washington Univer­
sity, the students may not. "The joke I use 
in speaking with them is that we're neither 
six blocks from the White House nor on 
Puget Sound," he says. 'The fact is, 
though, that a lot of them don't know where 
we are." 
They may also have misconceptions 
about graduate work. During his visits, 
Rhodes often gives a "neutral" seminar, ex­
plaining what students should look for in a 
Ph.D. program and what admissions com­
mittees will expect: "All sorts of things 
come up. Students may not realize how well 
qualified they are for graduate school. 
Sometimes they don't even know they can 
receive tuition and a stipend for their gradu­
ate work. They think they'll have to borrow 
the money." 
At some schools, Rhodes also finds that 
he's a new phenomenon. Though Princeton 
is beginning to initiate a similar program, 
other graduate institutions just don't do 
Washington University's kind of personal 
recruiting at the graduate level. A genial 
and energetic man with a strong concern for 
students, Rhodes has clearly provided some 
of the impetus for this major recruiting 
effort. When he arrived three years ago 
after administrative posts at NIH and Stan­
ford, the time seemed right: A rush of new 
faculty and a one-to-one faculty/student 
ratio were extremely attractive. After a 
lapse during the Nixon administration, 
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federal funding - primarily NIH training 
agents - was available. 
Since then, Rhodes has gained solid re­
spect for his work, says Ted R. Johnson, 
Ph.D., head of the Biology Department at 
St. Olaf College: "Frankly, we get lots of re­
quests by recruiters to give seminars, but 
we honor very few of them. Carl Rhodes' 
seminar, though, is extremely helpful to the 
students. " 
Even though he travels to big schools like 
the University of Washington and Cornell, 
Rhodes says that recruiting from them can 
be difficult. There may be more than 1,000 
undergraduates in the biological sciences at 
one of the larger schools; advising is often 
done on an alphabetical basis. He prefers to 
concentrate on small liberal arts colleges. 
Traditionally, they have a high percentage of 
science majors who go on to do weI I in re­
search. They also have an excellent track 
record here: since 1978, some 25 percent of 
division graduates have come from small 
colleges. 
These schools also supply the under­
graduates for Washington University's 
summer internship. Since 1982, when three 
biology students came from Kalamazoo 
College, the program has grown to a maxi­
mum of 15 students per summer, drawn 
from various colleges. These students, usu­
ally incoming seniors highly recommended 
by their own science professors, spend three 
months here working on a research project. 
'The idea is to give them a view of grad­
uate work at a large institution," says 
Rhodes. "But you might ask what's in it for 
us? We hope that when they go back, they 
will tell other students about the experience 
they had here," Rhodes says. 
One of last summer's group is Michael 
Kyzer, a chemistry major from Hendrix 
College in Arkansas. After working in the 
laboratory of Maynard V Olson, Ph.D., 
associate professor in the Department of 
Genetics, Kyzer is enthusiastic about his ex­
perience. "It's wonderful. I'm surprised 
they've allowed me to do so much indepen­
dently." He plans to tell other Hendrix stu­
dents about his summer internship. Will he 
apply here for graduate study? "Definitely," 
he says. 
In recruiting students to summer and 
graduate programs, Rhodes says, the repu­
tations of the divisions' 230 faculty mem­
bers play an important part. "If we didn't 
have a good faculty, it wouldn't matter what 
I did. We wouldn't attract anyone," he says. 
The innovative Washington University 
graduate program is also a strong selling 
point. In 1973, the Division of Biology and 
Biomedical Sciences was organized as a 
consortium of seven medical school depart­
ments, plus the Department of Biology on 
Hilltop campus. Rather than traditional 
concentrations along departmental lines, the 
new division offers five interdisciplinary 
programs: Molecular Biology and Bio­
chemistry, Cell and Integrative Biology, 
Plant Biology, Population Biology, and 
Neural Sciences. 
The 220 graduate students in the divi­
sion, which is now directed by Daniel 
Hartl, professor and head of genetics, still 
enjoy a sense of freedom unmatched at 
most institutions. During their first year, 
they can readily switch from one program 
to another. They can also rotate among two 
or three labs to see where personalities and 
research interests best mesh. 
This openness is a boon to recruiting, 
says Johnson of St. Olaf College, who last 
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Carl Rhodes, associnie director ofbiology and biomedical sciences, discusses research progress with an uruiergradua1e research intern, Jeff 
Zachs. In a program conceived by Rhodes, promising undergraduates receive research experience lUldfamiliarity with Washington Univer­
sity through summer internships. 
. ~ the division. "In many graduate schools, 
students come to work with a specific ad­
:j > • 
viser or in a designated area. At Washington 
University, they can shift around. For our 
students, whose interests L,ay not be 
focused yet , this is a great advantage." 
Julie Hatch , a Sl. Olaf graduate and 
"r . fourth-year student, used that freedom to 
pin down her own research interests. She 
stayed in her third rotation, working in the 
laboratory of Susan E. Cullen, Ph.D., asso­
ciate professor of genetics and microbiology 
and immunology. Now, she enjoys the spirit 
of cooperation that exists between pro­
grams. "There's a lot of interaction between 
departments. J'm interested in cell biology, 
but J hear what's going on in pathology and 
other areas," Hatch says. 
The Washington University graduate 
division is not for everyone. One summer 
student discovered his true vocation during 
his stay - and is now in a Lutheran semi­
nary. And those who wish to apply will find 
that the school is highly selective. Last year, 
of 450 applicants, only 85 were offered ad­
mission and 44 finally came. 
But Rhodes hopes that , through the vari­
ous aspects of his recruiting program, he 
can reach those students who would benefit 
by a Washington University graduate educa­
tion. Mike Kyzer is convinced. "I plan to go 
back to Hendrix with many, many positive 
things to say. The Washington University 
faculty is supportive and knowledgeable in 
many fields. Students can pursue their own 
interests and not just become satellites 
of an investigator. For a graduate student, 
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Howling at the Moon 
\ . -¢ 
The Unnatural History ofthe 1110vement 
Against AnimalExperimentation 
eventy years ago, infectious diseases 
stalked the land with far greater cer­
tainty of death than AIDS does now. 
Everyone could experience Mimi's hopeless 
agony as she slowly expired from con­
sumption (tuberculosis) in Puccini's "La 
Boheme." Surgical procedures that we now 
take for granted were still being developed 
and perfected; little could be done to stem 
the usually fatal course of post-operative 
infection. 
Progress in medical care is a testament to 
human imagination, the dedication of 
health care professionals, and society's abil­
ity to solve important problems. Studies 
using animals as research subjects have 
sharpened considerably the effectiveness of 
health care and broadened the scope of its 
services. Experiments on animals have led 
to corneal transplants (rabbits; Am. J 
Ophthal. 34 (1951): 142), immunization 
against polio (chimpanzees; Am. J Hyg. 5 I 
(1950): 85), removing blood clots (dogs; 
Circulation 72 (1985): 18), treatment of dia­
betes (dogs: J Lab & Clin. Med. 7 (1922): 
251), and the spectacular rise of cardiovas­
cular surgery (dogs; lAMA 128 (1945): 189). 
Better diagnosis, treatment and prevention 
have immeasurably improved the lives of 
humans and our animal brethren. 
Despite many spectacular advances, the 
future of scientific medicine is threatened in 
the name of "animal rights." Laboratories at 
the University of Pennsylvania Medical 
School were raided on the 1984 Memorial 
Day weekend. Sixty hours of videotapes 
documenting experiments for a head injury 
project were stolen by ALF (Animal Liber­
ation Front). Soon afterward, PETA (People 
for the Ethical Treatment of Animals) dis­
tributed a slick video, "Unnecessary Fuss," 
extracted from the stolen tapes. The PETA 
video, narrated by Ingrid Newkirk, is not 
pretty. It would turn the stomach of anyone 
not familiar with the tragedy of head 
injury and its devastating effects. Yet 
these stomach-churning experiments are 
one of the few hopes the victims and their 
families have. 
Last summer, in response to intense 
political pressure, then-Secretary of Health 
and Human Services Margaret Heckler 
suspended federal funding for the Penn re­
search. Subsequent raids on laboratories 
throughout the country have often been 
followed by surprise inspections of animal 
facilities and research laboratories by the 
National Institutes of Health (NIH). Early 
this year, all federal funds awarded to 
Columbia University were withheld for six 
months after such an inspection, no doubt 
further providing positive reinforcement for 
animal rights activists. 
Now, the NIH itself is under attack. 
PETA accuses the NIH of mishandling the 
care of a group of monkeys seized several 
years ago from a Silver Springs, Md., 
laboratory. The activists have enlisted 
.....  ~ 
Congressional support in pressuring the 
NIH to tum the animals' care over to a pri­
vate sanctuary. 
The response of individuals in the 
biomedical community to these challenges 
has been slow, weak and poorly organized. 
Is this because we believe that the problem 
will go away? If history tells us anything, it 
is that this bel ief is patently absurd. 
The animal rights movement is not new; 
it sprang up in eighteenth-century England 
and America as a radical offshoot from 
humane societies. Then, as today, humane 
societies provided essential services, such as 
caring for and disposing of stray dogs and 
cats. Antivivisectionists, as the radicals 
were then called, attempted to abolish 
animal experimentation and, failing that, 
to regulate it into oblivion. 
Antivivisectionists in the 1800s assumed 
that all animal experimentation was painful 
..,
and cruel. They also accused sciyntists of 
being immoral atheists and questioned the 
,.. 
validity of scientific progress. Boldly politi­
cal tacticians, anti vivisectionists had "cells" . ;;. 
located in cities. These vigorous, well­
financed, political organizations recruited 
supporters, published pamphlets and won 
over influential clergy and politicians. Their 
efforts were rewarded by the Cruelty to 
Animals Act of 1876, which is still the basis 
for regulation of animal experimentation in 




As early as 1867, attempts at similar 
legislation began in the United States. The 
leaders of American medicine organized 
strong, successful opposition to the Con­
gressional bills of 1896 and 1900. Their case 
~ .. 
was bolstered by the demonstrated value of 
-, .... 	 animal research in surgical antisepsis (pub­
lished by Lister in 1867, based on his direct 
observations on inflammation in experi­
mental animals), antitoxin treatment for 
diphtheria (introduced by Behring in 1893, 
. , 	 after he and Kitsato demonstrated that 
serum from animals exposed to diphtheria 
toxin protected other animals from the 
disease), and other discoveries that im­
proved the health of humans and animals. 
Re-emerging in cyclical fashion throughout 
this century, the animal rights movement 
has gained renewed strength. 
Historians have examined the movement 
with a dispassionate eye. They note that 
antivivisection agitation preceded animal 
experimentation in English and American 
medical schools. In the historians' view, 
concern over animal welfare masked 
ulterior motives. Under the powerful rally­
ing cry of antivivisection seethed other con­
cerns: nationalism, political expression for 
unenfranchised women, and difficult-to­
articulate problems like the displacement , ~". .. 
squalor and suffering brought on by the 
-+ industrial revolution. 
Since the concept of animal rights is not 
", . 
new, nor is the sensitivity to animal suffer­
ing, it is not clear whether ulterior motives 
underlie the present resurgence opposing 
animal experimentation and harvesting of 
animals for food, clothing and sport. 
On the Today show of July 18, 1985, 
PETA's Newkirk commented: "If it [animal 
experimentation] were such a valuable way 
.. 
.... [to gain knowledge] we should have eternal 
life by now." This refrain is strikingly 
similar to one made by antivivisectionist 
... 	 Matthew Woods in 1900: Given the number 
of experiments on the brain done up to 
that time, he said, the insane asylums of 
Washington, DC should be empty. 
Indeed, most of the current strategies are 
strikingly similar to those of antivivisec­
tionists : publicize, misrepresent, find sup­
portive "medical friends" and atlempt to J_I + 
limit funds for biomedical research. Even 
Tho/1UIS A. Woolsey, M.D. 
more ominous are the breaking into, the 
theft from and the destruction of laborato­
ries, and the direct threats on the lives 
of working scientists. 
Those who advocate the cessation of 
animal experimentation have the right to 
express themselves. But how humane is it to 
deprive of hope victims of senile dementia , 
stroke and cancer - problems that affect a 
growing proportion of our population with 
almost unbearable immediacy? Answers 
can only come after years of intensive study 
on experimental animals. It is clearly in our 
interest to adopt alternatives to animal 
experimentation - models - when these 
models more quickly lead to the right 
answers. But at present, there are no 
suitable experimental models that can be 
substituted for animal experimentation in 
research on senile dementia, stroke 
and cancer. 
Scientists are not inhumane, immoral 
monsters who delight in torturing helpless 
creatures. On the contrary, we have that 
exceptionally deep respect for all of life, 
including human, that can only come from 
years of intensive study. As health profes­
sionals, we feel a deep sense of responsi­
bility to those we serve. I believe that part of 
that responsibility is making sure, to para­
phrase Dr. Mary Putnam Jacobi in 1900, 
that "knowledge is not dominated by igno­
ranee." The record is clear; careful , well­
thought-out experiments on animals have 
vastly improved veterinary practice and 
medical care. Such work can make, and has 
made, the difference for their well-being 
and ours . 
Thomas A. Woolsey, M.D. 
Professor, Anatomy and Neurobiology and 
Cell Biology and Physiology 
George H. and Elhel R. Bishop Scholar 
in Neuroscience in Neurology and 
Neurological Surgery 
Professor ofNeurology and Neurological 
Surgery 
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aulo. Hagemann, M.D. 
'34, clinical professor 
emeritus of the Wash­
ington University School of 
Medicine, has received the 
prestigious William Greenleaf 
Eliot Society Award. 
William Van Cleve, presi­
dent of the Eliot Society, pre­
sented Hagemann with a silver 
and marble replica of the sculp­
ture 'The Search," designed 
by Heikki Seppa, professor of 
art at the university. 
Hagemann, an active parti­
cipant in alumni affairs, is a 
life member of the Eliot Soci­
ety. He has served on the 
university's Alumni Board of 
Governors and now is vice 
chairman in charge of the 
Planned Giving Committee. 
Hagemann was a key person in 
the development of the plrinned 
giving program and has estab­
lished an endowed scholarship 
in the School of Medicine. His 
leadership in the Medical 
Center Alumni Association 
began early when he served as 
chairman of the flfth reunion of 
his class of 1934. 
Marvin Levin, M.D. '51, 
professor of clinical medicine, 
who served both his residency 
and internship under Hage­
mann, calls him an "astute and 
caring" physician. "He had a 
good relationship with his pa­
tients," recalls Levin. "He set a 
good example for his students, 
interns and residents. " 
The Eliot Society is an or­
ganization of university alumni 
and friends. The society is 
named after the university's 
founder, the Rev. William 
Greenleaf Eliot. Each year the 
society honors an individual 
who has given outstanding ser­
vice to the university, chosen 
by an anonymous committee of 
the society's members. Last 
year's award recipient was 
PaulO. Hagemann, M.D. 
Zane E. Barnes, chairman and 
chief executive officer of 
Southwestern Bell Corp. 
Hagemann is a graduate of 
the Washington University Col­
lege of Arts and Sciences and 
received his medical degree 
from the university's School of 
Medicine. After his internship 
at New York Hospital, he be­
came an assistant resident at 
New Haven Hospital in Con­
necticut, where he was a 
Sterling Fellow in the research 
department. He returned to the 
Washington University Medical 
Center in 1937 to work as a 
resident at Barnes Hospital. He 
later joined the faculty of the 
School of Medicine as an in­
structor in medicine. 
By 1944 he was serving as 
assistant professor of cI in ical 
medicine and director of the 
Barnes Hospital laboratories 
when his service with the U.S. 
Army took him to Los Alamos 
with the Manhattan Project. 
Hagemann was part of the 
team that monitored the first 
atomic explosion in New 
Mexico. He later traveled to 
Hiroshima, Japan, to evaluate 
residual radiation in that area. 
Hagemann returned to his 
private practice and teaching 
responsibilities at the School of 
Medicine in 1946. He was later 
appointed chief of medicine at 
St. Luke's Hospital and estab­
lished the training program 
there that serves as Washington 
University's Postdoctoral Pri­
mary Care Training Program 
in Internal Medicine. 
He has served as a Diplo­
mate of the American Board of 
Internal Medicine, and was 
given the Distinguished 
Alumni Award at Founders 
Day in 1983 and the School of 
Medicine's Alumni/Faculty 
Award in 1984. 
Tom F. Wha)'ne, M.D. '31, 
is professor emeritus at the 
University of Kentucky College 
..
of Medicine. He is writing a 
history of preventive medicine 
in World War II and directing a 
program on the Oral History of 
Medicine in Lexington and 
Fayette County, KY 
Robert A. Wise, M.D. '36, 
is professor of public health 
and occupational medicine at 
the University of Texas School 
of Public Health, and clinical 
professor of internal medicine 
at Baylor College. 
O. Elliott Ursin, M.D. '36, 
served in the U.S. Army Medi­
cal Corps for 32 years, and re­
ceived a distinguished service 
medal. After retirement, he 
attended the University of Oslo 
for one semester, and then was 
medical director of a nursing 
home in San Antonio. 
Lawrence W. O'Neal, 
M.D. '46, is chairman of the 
Department of Surgery at 
SI. John's Mercy Medical 
Center in St. Louis and pro­
fessor of clinical surgery at 
St. Louis University. 
Ann DeHuff Peters, M.D. 
'46, is clinical professor of 
pediatrics at the School of 
Medicine, University of 
California at San Diego. She l. .. 
was president of the American 
Orthopsychiatric Association 
in 1981. 
Harry S. Jonas, M.D. '52, 
FHS, dean of the University of 
Missouri-Kansas City School 




president of The American He has served four terms as sonal achievement in original of medicine. He was promoted 
College of Obstetricians and a member of the regional research. His interests center to associate professor in 1973 
Gynecologists (ACOG). screening panel of the Presi- on the immunological.aspects and to professor in 1978. 
As a private practitioner in dent's Commission of White of arthritis and the improve- Within the Department of 
Independence, MO, from 1956 House Fellowships. A member ment of diagnostic procedures Medicine at UCLA, Schultze 
until 1975, Jonas delivered of several professional soc ie- for certain immunological dis- has served as chief of the divi­
more than 7,000 babies. He be- ties, he has authored a number eases, particularly systemic sion of nephrology, executive 
came full-time professor of of scientific journal articles and lupus erythematosus and poly- vice chairman and acting chair-
obstetrics and gynecology at textbook contributions. myositis, an inflammation of man. He was associate dean for 
the University of Missouri- Jonas completed his OBI the muscles. administration in UCLA 
-; 	
Kansas City School of Medi- GYN residency at Barnes- Raymond G. Schultze, School of Medicine from 1979 
., 	 cine, and chairman of the OBI St. Louis Maternity and M.D. '59, became administra- to 1986. 
GYN department at Truman St. Lukes hospitals. tive vice-chancellor and direc- William I. Goettman, 
Medical Center, the Univer- Jean A. Chapman, M.D. tor of UCLA Medical Center M.D. '58, was inducted into 
sity's teaching hospital. Since '53, FHS, of Cape Girardeau, Wittenberg University's Ath­
1978 he has been dean of the MO, a specialist in internal letic Hall of Honor. 
medical school. medicine and allergy, has been Goettman was co-captain, 
Jonas was instrumental in elected to Fellowship in the Most Valuable Player, All-Ohio 
the successful passage of a American College of Physi- Athletic Conference and AII-
public bond issue which built cians (ACP). Ohio for the 1952 and 1953 bas­
.~ 
the teaching hospital for the Chapman received a B.S. ketball seasons at Wittenberg. 
medical school. Truman Medi- degree frol11 Southeast Mis- He set what was then a school 
cal Center is a public hospital souri State College in Cape single-game scoring record 
serving a large number of indi- Girardeau in 1949, and an addi­ with 38 points against Ohio 
gent patients, including many tional B.S. in medicine with an Wesleyan. Goettman was also a 
who are high-risk obstetrical M.A . in Anatomy from the standout tennis player, holding 
patients. University of Missouri in 1951. the number one spot in singles 
He has held many positions After completing his M.D. , he and serving as captain of the 
with state, regional, and na- went on to become a medical doubles team. 
tional OB/GYN societies. For resident at St. Louis City Hos- A Danforth Scholar, 
- 1. ... 

the past 25 years he has been pital on the Washington Uni- Goettman served 12 years as 

~; an active member of ACOG. versity Service. team physician for the Tigers' 
Raymond G. Schultze, M.D.He chaired the College's Health Daniel M. Divack, M.D. athletic squads. He was a chair 
Care Commission , which '56, is an obstetrician and of the Tiger Fund during "The 
studies and makes recommen- gynecologist in private practice on September I. He has been Campaign for Wittenberg" that 
dations on those issues facing with appointments at Long the center's director since 1980. raised over $20 million. 
practitioners of obstetrics Island Jewish Hospital and the The combined appointment 
and gynecology. He chaired State University of New York at links responsibility for man-
ACOG's Missouri Section and Stony Brook . agement of the 71 I-bed center '60. 
the South Central District and Havner H. Parish, M.D. with administrative functions 
was a member of the national '56, retired after 25 years of for the campus. John T. Crosson, M.D. 
Committee on Professional private practice in urology. He Schultze holds the B.A. and '61, is associate professor in 
Liability. For the past year, he lives in Pittsboro, NC, is a pilot M.D. from Washington Univer- the Department of Laboratory 
served on ACOG's executive and plays the bassoon. sity. He served his internship Medicine and Pathology at the 
board as the president-elect. Morris Reichlin, M.D. and residency at UCLA. University of Minnesota. His 
He is chairman of the '59, received the 1986 Provost's In 1965, he returned to hobbies include tennis, music 
Obstetrics Section of the Research Award from the Uni- Washington University as a and running, and he has 
Southern Medical Association, versity of Oklahoma Health United States Public Health completed four marathons. 
a board member of the Truman Sciences Center. A professor of Service Postdoctoral Fellow, Phillip E. King, M.D. '61, 
Medical Center, past member medicine in the au College of and was also appointed to the is associate clinical professor in 
of the Governor's Task Force Medicine, Reichlin was one of faculty as instructor and then radiology at West Virginia 
on Rape Prevention, and past two recipients of the annual assistant professor of medicine. University Medical School. He 
president of the Kansas City award, which recognizes per- Returning to UCLA in 1969, --- . ~ . 





also has a private practice 
and appointments at several 
hospitals. 
Carl Mitchell, M.D. '61, is 
in private practice in Nashville, 
TN, and is clinical assistant 
professor of medicine at 
Vanderbilt University and the 
University of Tennessee. 
Gordon W. Philpott, M.D. 
'61, is professor of surgery at 
Washington University School 
of Medicine. His hobbies are 
fishing, photography and vege­
table gardening. 
Shigemi Sugiki, M.D. '61, 
is associate clinical professor 
of ophthalmology at the Uni­
versity of Hawaii School of 
Medicine. He also has appoint­
ments at Kuakini, Straub and 
St. Francis hospitals and the 
Queen's Medical Center. This 
year he became president of 
the Hawaii Ophthalmological 
Society. He is also an instructor 
in aikido. 
H. Michael Jones, M.D. 
'66, a specialist in pathology 
and nuclear medicine, is in solo 
practice in Henderson, NC. He 
also heads a recruitment pro­
gram that has tripled the 
number of physicians in his 
rural area. 
Donald R. Kirks, M.D. 
'68, currently professor of ra­
diology and pediatrics at Duke 
University Medical Center, has 
been appointed chairman of 
the Department of Radiology 
at Children's Hospital Medical 
Center, Cincinnati, OH, and 
professor of radiology and 
pediatrics, University of Cin­
cinnati College of Medicine, 
effective September 1, 1986. 
The 330-bed pediatric institu­
tion is the largest children's 
hospital in the United States. 
Approximately 70,000 pediat­
ric imaging examinations (con­
ventional diagnostic x-ray, 
ultrasonography, computed to­
mography, nuclear medicine, 
digital radiography, angiogra­
phy, interventional procedures, 
magnetic resonance ,imaging) 
are performed annually. 
Kirks, chief of the section of 
pediatric imaging in the De­
partment of Radiology, has 
been at Duke University Medi­
cal Center since 1978. He is 
secretary of The Society for 
Pediatric Radiology and chairs 
the pediatric radiology pro­
gram for the Radiological Soci­
ety of North America. As 
member of the Executive Com­
mittee of the Association of 
University Radiologists, Kirks 
is editor of Pedifuru: Radiolog): 
associate editor of Radiology, 
reviewer for the American lour­
nalo/Roentgenolog): and ex­
aminer for the American Board 
of Radiology. 
Dr. Kirks has published over 
250 abstracts, scientific papers, 
review articles, and textbook 
chapters during his .14 years in 
academic pediatric radiology. 
His textbook, Practical Pediat­
ric fmLlging : DingIWstic Radiol­
ogy o/In/ants and Children, 
was published by Little, Brown 
and Company in 1984. He re­
ceived the John Caffey Award 
of The Society tor Pediatric 
Radiology in 1979 and the 
William E Barry, Jr. Resident 
Teaching Award of the Depart­
ment of Radiology at Duke 
University Medical Center 
in 1985. 
Kirks, a native of Ft. Worth, 
TX, received his B.A. from 
Rice University in 1964 and 
M.D. from Washington Univer­
sity School of Medicine in 
1968. After a medicine intern­
ship at Parkland Memorial 
Hospital in Dallas, Kirks com­
pleted a residency in diagnostic 
radiology at the University of 
California, San Francisco 
Medical Center and a fellow­
ship in pediatric imaging at 
The Hospital for Sick Children 
in Toronto. He was a staff pedi­
atric radiologist at Children's 
Hospital Medical Center, 
Oakland, CA, and Children's 
Medical Center, Dallas. TX, 
before joining the Department 
of Radiology at Duke 
University. 
Roger Warnke, M.D. '71, 
is associate professor of pathol­
ogy at Stanford University 
School of Medicine. 
Darwin C. Jackson, M.D. 
'76, an obstetrician and gyne­
cologist, has appointments at 
Washington University School 
of Medicine and Barnes, 
Jewish and Deaconess hospi­
tals in St. Louis. His awards 
include Teacher of the Year, 
1983-84 from the Department 
of Obstetrics and Gynecology. 
and Outstanding Young Men of 
America, 1985. 
William Kaufman, Ph.D., 
M.D., FHS, of Stratford, Con­
necticut, presented his paper 
"Niacinamide Improves 
Mobility in Degenerative Joint 
Disease" before the Bio­
chemistry and Pharmacology 
Section of the 152nd Annual 
Meeting of the American 
Association tor the Advance­
ment of Science held recently 
in Philadelphia. 
Leo A. Whiteside, M.D., 
FHS, was named a member of 
the Board of Directors of the 
American Academy of Ortho­
pedic Surgeons at the associa­
tion's recent annual meeting in 
New Orleans. 
Whiteside is chief of ortho­
pedic surgery and director of 
the biomechanical lab at DePaul 
Health Center, Bridgeton, Mo. 
He is research assistant pro­
fessor of orthopedic surgery at 
Washington University. 
Born in Pampa, Texas, 
Whiteside has a B.S. from the 
University of Oklahoma and an 
M.D. from the University of 
Texas, where he was honored 
by Alpha Omega Alpha when 
he received the Student Re­
search Award in 1968 and 1969. 
Whiteside is a member of 16 
medical associations and is 
also editor of Clinical artho­
pedic and Relnted Research and 
The lourrull ofArthroplasty. 
Medical Center Alumni 
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St. Louis, MO 63110 
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• Patricia Newt 
atricia A. Newton, M.D. '75, travels 
through life with giant strides that 
would make Paul Bunyan proud. 
At the age of 40, this Baltimore psychiatrist 
has already packed more into her career 
than most people would by retirement. 
"I knew when I was 8 that I wanted to go 
into medicine," she says. "They gave me a 
nurse's cape, but I didn't want that. 
I wanted a black bag with a stethoscope 
in it." 
None of Pat Newton's progress could sur­
prise those who knew her as the spirited, 
high-achieving, determined and somewhat 
unorthodox daughter of scholar-educators 
in her native Tuckerman , Ark. After aU , 
this is the young woman who as a child 
broke a gi ft doll because she preferred 
cowboy guns. 
The diminutive doctor-to-be won a third­
degree black belt in karate, went in for 
weight lifting and aerobics, excelled in 
Spanish and piano, hated math, played bas­
ketball as a 5 ' 2/1 forward, became the only 
pre-med member of the school touring choir 
and refused to leave that group, even though 
a faculty member worried that she was 
trying to do too much. 
Always an excellent student, she gradu­
ated from high school at 15 - just as her 
mother, then living in St. Louis, had done 
20 years earlier. Before entering medical 
school , she obtained her bachelor of science 
degree in pre-medicine from the University 
gres 
Patricia Newton, who graduated from the 
School ofMedicine ill 1975, is now presi­
dent ofan international behavioral science 
management ronsultingfirm in Baltimore, 
and assistant professor ofpsychiatry at 
Johns Hopkins University. 
of Arkansas in Pine Bluff, and graduated 
magna cWlllaude from VanderbiJt Univer­
sity with her master's in molecular biology. 
While still in school, she worked as a 
microbiologist for the state of Tennessee. 
After receiving her medical degree, 
she became a resident in psychiatry, then 
chief resident and instructor in clinical psy­
chiatry at Washington University School 
of Medicine. 
Her next stop was Baltimore, where she 
took a second master's degree, this one in 
public health from Johns Hopkins School of 
Hygiene and Public Health. She then joined 
the staff of Provident Hospital where, as 
psychiatrist-in-chief, she instituted pioneer 
programs for the rehabilitation of the 
chronically mentally ill. She spurred the 
hospital's sponsorship, together with the 
National Institute of Mental Health, of the 
first Baltimore International Congress of 
Transcultural Psychiatry. The Congress 
brought exchange scientists from all over 
the world, more than 600 participants from 
25 nations. 
Newton has resigned that hospital POSt to 
concentrate on her other professional inter­
ests, but she remains an innovative leader 
in the mental health area. President and 
medical director of Behavioral Medicine 
Associates, Inc. in Baltimore, she is editor 
of that organization's health information and 
educational service, president of Newton­
THOTH, Inc., an international behavioral 
science management consultant firm, and 
on the faculty of Johns Hopkins University 
as assistant professor of psychiatry. 
Her research centers on the effects of 
medical e.lectrical acupuncture in stress 
management and in chronic pain. 
Honor has followed closely on the 
heels of achievement. As a distinguished 
Marylander in medical science, she was 
appointed to the Governor's Task Force on 
31 
Alzheimer's Disease in Maryland and to the 
State Advisory Council on Mental Hygiene. 
In 1983, Baltimore Magazine cited her as one 
of the city's "100 most intluential women." 
Essellce, the nation's only black women's 
litestyle magazine, chose her as "Woman of 
the Year in Health and Medicine" in 1985 in 
commemoration of the 15th anniversary of 
the publication honoring black women who 
have made outstanding contributions to 
American society. 
A love of scholarship and education, 
in whatever field, was as much a part of 
her heritage as is her name. Her father, 
McKinley Newton, was her high school 
principal in Tuckerman; her mother, tbe 
former Bernice lones, was on the faculty 
and coached basketball. They now live in 
Little Rock, where her father is vice chan­
cellor of Philander Smith College. Both are 
graduates of Pat's alma mater in Pine Bluff. 
"I studied science and math with Dad 
and English with Mother. She was one of 
the pioneer women's basketball coaches. 
It was tough having her as a coach. I didn't 
get any breaks," says Newton. 
In Newton's high school days in Arkan­
sas, she developed a special interest in 
drama and later parlayed that interest into a 
theater group for her patients. 
"This started when I was head of psy­
chiatry at Provident. We were looking for a 
way to give chronically mentally ill patients 
a way of rehabilitation. 
"While I was lecturing at the University 
of West Indies, I ran across a doctor who 
was director of the lamaican Psychiatric 
Services. He had trained in Edinburgh 
and had begun to rehabilitate chronic pa­
tients using the European technique called 
sociodrama. " 
Adapting the technique to her own hospi­
tal population, she developed a highly suc­
cessful program for her patients: "They 
toured the area and played at lohns Hopkins 
and several other hospitals. They developed 
their own bank account and a couple of 
them got jobs in theater arts, on stage crews 
and similar work . 
"This takes the chronically ill patients, 
gets them out of the regressive arena so they 
are able to interact and socialize and go out 
and get jobs. It's a form of social reinte­
gration, helping to prevent relapse because 
they can better manage and manipulate 
their environments. 
"It was not a substitute for medication. It 
was run as an adjunct to help people re­
socialize. From that group we developed a 
research program to carry those people for­
ward. The state of Maryland developed 
something called psychosocial rehabilitation 
incJudingjob training for the mentally ill, 
and this patient group had all the skills to 
take full advantage of that program," ex­
plains Newton. 
Even though her work with the chroni­
cally mentally ill sparks a missionary zeal, 
Newton also is concerned with those who 
are not so disabled enough to be institution­
alized but who are, nevertheless, buffeted 
by the tensions of modern society. 
"(.n my private practice, we have a multi­
specialty, doing a lot of prevention such as 
stress reduction, weight control and smok­
ing cessation. We still treat the typical 
psychiatric patient, but my whole emphasis 
is on behavioral change and prevention." 
One of her greatest concerns - even 
though she is unmarried with no children 
of her own - is the problem of youth 
su icide, a symptom of society's late 20th­
century ills. 
"Generations ago, there were not so 
many drugs available, not as much disin­
tegration of the family," she says, as she 
considers the causes of human stress. 









more single parents, and a lot more for chil­ .I'- " J~ 
dren to get exposed to. We have a society I, 
that believes in instant gratification. We "r­
have a lot more violence, more child abuse, 
spouse abuse, teenage pregnancies - and 
suicide. According to the Youth Suicide 
Prevention National Committee, 500,000 
persons between the ages of 15 and 24 try to 
kill themselves every year; 5,000 succeed." 
Is there a cure, or, at least, a palliative? 
Her answer comes swiftly. "It has to start 
with re-education. I think it's too late for 
many of our children. I think we will have 
to change the structure of education. 
"Children are having to make adult deci­
sions long before they have adult mentality. 
They are exposed to material things without 
any kind of value system. Coupled with 
that is the threat of the present competitive t .- -, 
environment. lobs are being taken away. 
People are getting out of school while func­
tionally illiterate." 
The answer, she says, "should come from 
the family, but the family isn't there any­
more. The only other place is the school 
system and groups of parents lending a ··t·(
hand in some kind of collective support sys­
tem. If we don't do something, we will have I
-.;._ .0 • . ca society of animals. None of us will be 
sate." 
How does she maintain her own sanity? 
And how can others? "First of all," she says 
with a laugh, "I thank God for good genes. 
I was fortunate enough to have parents 
who were not overly protective but did pro­
. . ( 
tect me from certain things. I had a good 
family support system that was caring and 
loving and believed in allowing children to 
develop normally. 
"The other side of this is that I have seen 
every kind of bad human behavior, and it all 
comes to a very common denominator­
many of these people are not loved and 
nurtured." \. -".
She stresses the importance of "having 
~ 
the nurturance of good friends and family 
and the sanity to know that when things are 
overwhelming, you can give them up. And, 
remember, a little cry never hurts. We have 
to accept our own limitations and be able to 
, . ' .., 
let go and move on to the next level without 
feeling guilty about it. Only God is per­ -- .1 
fect. " 
"_. L 












A chance to conduct research under the direction ofintenzat iollally recog­
nized scientists can help undergraduates make career choices and entice 
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During orielltntwn week, this year's 120 freshmen JuuJ a chance to get 
acquainted at a buffet supper at St. Charles Wine Gardell. The annual 
freshmen welcoming party, which is sponsored by Washington University 
Medical Center Alumni Associatwn,Jollows a bus tour ofSt. Louis. 
0<, 
